Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q/A

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2023

☐	TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____________

Commission File Number: 333-229399

BIONEXUS GENE LAB CORP.

(Exact name of registrant as specified in its charter)

Wyoming		35-2604830
(State or Other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification No.)

Unit 02, Level 10 Tower B, Avenue 3, The Vertical Business Suite II Bangsar South No. 8 Jalan Kerinchi Kuala Lumpur, Malaysia		59200
(Address of Principal Executive Offices)		(Zip Code)

+1307 241-6898

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, no par value		BGLC		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer, “ “ accelerated filer, “ “non-accelerated filer ,” “ smaller reporting company, “ and “ emerging growth company “ in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated Filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of November 20, 2023, there were 17,667,663 shares of common stock, no par value per share, issued and outstanding.

TABLE OF CONTENTS

		Page
PART I – FINANCIAL INFORMATION
Item 1.	Financial Statements	4
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	22
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	30
Item 4.	Controls and Procedures	31

PART II – OTHER INFORMATION

Item 1.	Legal Proceedings	32
Item 2.	Unregistered Sale of Equity Securities and Use of Proceeds	32
Item 3.	Defaults Upon Senior Securities	32
Item 4.	Mine Safety Disclosures	32
Item 5.	Other Information	32
Item 6.	Exhibits	33
SIGNATURES		34

Table of Contents

CAUTIONARY NOTE REGARDING

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q/A contains statements that may be deemed to be “forward-looking statements” within the meaning of the federal securities laws. These statements relate to anticipated future events, future results of operations and or future financial performance. In some cases, you can identify forward-looking statements by their use of terminology such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “future,” “intend,” “may,” “ought to,” “plan,” “possible,” “potentially,” “predicts,” “project,” “should,” “will,” “would,” negatives of such terms or other similar terms. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The forward-looking statements in this Quarterly Report on Form 10-Q/A include, without limitation, statements relating to:

	●	our goals and strategies;

	●	our future business development, results of operations and financial condition;

	●	our estimates regarding expenses, future revenues, capital requirements and our need for additional financing;

	●	our estimates regarding the market opportunity for our services;

	●	the impact of government laws and regulations;

	●	our ability to recruit and retain qualified personnel;

	●	our failure to comply with regulatory guidelines;

	●	uncertainty in industry demand;

	●	general economic conditions and market conditions in the financial services industry;

	●	future sales of large blocks or our securities, which may adversely impact our share price; and

	●	depth of the trading market in our securities.

The preceding list is not intended to be an exhaustive list of all of our forward-looking statements. Forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties, including those described in Item 1A “Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and elsewhere in this Quarterly Report on Form 10-Q/A.

You should not unduly rely on any forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Quarterly Report on Form 10-Q/A, to conform these statements to actual results or to changes in our expectations.

Table of Contents

ITEM 1. Financial Statements

BIONEXUS GENE LAB CORP.

CONDENSED CONSOLIDATED BALANCE SHEETS

AS OF SEPTEMBER 30, 2023 AND DECEMBER 31, 2022

(Currency expressed in United States Dollars (“US$”))

			As of
			September 30,			December 31,
	Note		2023			2022
			(Unaudited)			(Audited)
ASSETS
CURRENT ASSETS
Cash and bank balances				4,704,785			611,849
Fixed deposits placed with financial institutions				1,442,098			1,507,015
Trade receivables		3		900,396			2,868,364
Other receivables, deposits and prepayments				110,793			25,240
Tax recoverable		4		3,838			31,551
Inventories				1,107,917			977,807
Total current assets				8,269,827			6,021,826

NON-CURRENT ASSETS
Operating lease right of use assets		5		147,916			55,730
Property, plant and equipment, net		6		1,496,562			1,511,708
Other investments		7		1,551,217			1,150,898
Total non-current assets				3,195,695			2,718,336
TOTAL ASSETS			$	11,465,522		$	8,740,162

LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES
Trade payables		8		1,569,992			1,861,015
Other payables and accrued liabilities				29,776			103,370
Current portion of operating lease liabilities		5		33,897			16,569
Advance payment from customer				8,218			23,123
Tax payables				2,177			-
Total current liabilities				1,644,060			2,004,077

NON-CURRENT LIABILITIES
Non-current portion of operating lease liabilities		5		104,867			40,206
Deferred tax liabilities		4		28,880			30,866
Total non-current liabilities				133,747			71,072
TOTAL LIABILITIES			$	1,777,807		$	2,075,149

STOCKHOLDERS’ EQUITY
As at September 30, 2023, common stock, no par value; 300,000,000 shares authorized and 17,792,663 shares outstanding, and preferred stock, no par value; 30,000,000 shares authorized and no shares outstanding. As at December 31, 2022, common stock, no par value; 300,000,000 shares authorized and 14,476,513 shares outstanding, and preferred stock, no par value; 30,000,000 shares authorized and no shares outstanding (on a post-reverse stock split basis)*.		10		17,281,315			10,929,574
Additional paid in capital				(5,011,891	)		(5,011,891	)
Accumulated (losses)/surplus				(1,781,114	)		1,156,392
Accumulated other comprehensive losses				(800,595	)		(409,062	)
TOTAL STOCKHOLDERS’ EQUITY				9,687,715			6,665,013

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY			$	11,465,522		$	8,740,162

* Issued and outstanding shares of common stock have been adjusted for the periods prior to July 20, 2023, to reflect the 12-for-1 reverse stock split effected on that date on a retroactive basis as described in Note 10.

See accompanying notes to the condensed consolidated financial statements.

Table of Contents

BIONEXUS GENE LAB CORP.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

	Three months ended						Nine months ended
	September 30,						September 30,
	2023			2022			2023			2022
REVENUE	$	2,553,686		$	2,575,086		$	7,497,739		$	8,089,132

COST OF REVENUE		(2,199,354	)		(2,275,587	)		(6,434,796	)		(7,169,329	)

GROSS PROFIT		354,332			299,499			1,062,943			919,803

OTHER INCOME		199,284			54,110			511,792			153,340

OPERATING EXPENSES
General and administrative		(3,082,128	)		(418,824	)		(4,426,077	)		(1,241,631	)

LOSS FROM OPERATIONS		(2,528,512	)		(65,215	)		(2,851,342	)		(168,488	)

FINANCE COSTS		(4,259	)		(2,072	)		(9,746	)		(7,717	)

LOSS BEFORE TAX		(2,532,771	)		(67,287	)		(2,861,088	)		(176,205	)

Tax expense		(76,418	)		(10,114	)		(76,418	)		(22,792	)

NET LOSS	$	(2,609,189	)	$	(77,401	)	$	(2,937,506	)	$	(198,997	)

Other comprehensive income:
Foreign currency translation loss		(18,603	)		(320,592	)		(391,533	)		(707,128	)
COMPREHENSIVE LOSS	$	(2,627,792	)	$	(397,993	)	$	(3,329,039	)	$	(906,125	)

Earnings per share - Basic and diluted		(0.157	)		(0.028	)		(0.218	)		(0.063	)
Weighted average shares outstanding and per share amount have been adjusted for the periods shown to reflect the 12-for-1 reverse stock split effected on July 20, 2023, on a retroactive basis as described in Note 10.		16,774,370			14,476,513			15,250,883			14,409,733

See accompanying notes to the condensed consolidated financial statements.

Table of Contents

BIONEXUS GENE LAB CORP

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

AS OF SEPTEMBER 30, 2023 AND 2022

(Amount expressed in United States Dollars (“US$))

											Accumulated
	Common stock				Additional paid in			Accumulated			other comprehensive			Total
	Number of shares		Amount		capital			surplus			loss			Equity
Balance as of December 31, 2021		14,268,180	$	10,779,574	$	(5,011,891	)	$	1,512,358		$	(100,262	)	$	7,179,779
Net profit for the period		-		-		-			17,066			-			17,066
Foreign currency translation loss		-		-		-			-			(68,776	)		(68,776	)
Balance as of March 31, 2022		14,268,180	$	10,779,574	$	(5,011,891	)	$	1,529,424		$	(169,038	)	$	7,128,069
Net loss for the period		-		-		-			(138,662	)		-			(138,662	)
Issuance of shares		208,333		150,000		-			-			-			150,000
Foreign currency translation loss		-		-		-			-			(317,760	)		(317,760	)
Balance as of June 30, 2022		14,476,513	$	10,929,574	$	(5,011,891	)	$	1,390,762		$	(486,798	)	$	6,821,647
Net loss for the period		-		-		-			(77,401	)		-			(77,401	)
Foreign currency translation loss		-		-		-			-			(320,592	)		(320,592	)
Balance as of September 30, 2022		14,476,513	$	10,929,574	$	(5,011,891	)	$	1,313,361		$	(807,390	)	$	6,423,654

	Common stock				Additional paid in			Accumulated			Accumulated other comprehensive			Total
	Number of shares		Amount		capital			surplus			loss			Equity
Balance as of December 31, 2022		14,476,513	$	10,929,574	$	(5,011,891	)	$	1,156,392		$	(409,062	)	$	6,665,013
Net loss for the period		-		-		-			(69,066	)		-			(69,066	)
Foreign currency translation loss		-		-		-			-			(39,039	)		(39,039	)
Balance as of March 31, 2023		14,476,513	$	10,929,574	$	(5,011,891	)	$	1,087,326		$	(448,101	)	$	6,556,908
Net loss for the period		-		-		-			(259,251	)		-			(259,251	)
Foreign currency translation loss		-		-		-			-			(333,891	)		(333,891	)
Balance as of June 30, 2023		14,476,513	$	10,929,574	$	(5,011,891	)	$	828,075		$	(781,992	)	$	5,963,766
Net loss for the period		-		-		-			(2,609,189	)		-			(2,609,189	)
Round up shares		1,044,351		1,046		-			-			-			1,046
Issuance of shares*		1,437,500		5,750,000		-			-			-			5,750,000
Issuance of shares#		834,299		600,695		-			-			-			600,695
Foreign currency translation loss		-		-		-			-			(18,603	)		(18,603	)
Balance as of September 30, 2023		17,792,663	$	17,281,315	$	(5,011,891	)	$	(1,781,114	)	$	(800,595	)	$	9,687,715

Share activity (number of shares or both number and amount of shares) has been adjusted for the periods shown to reflect the 12-for-1 reverse stock split effected on July 20, 2023, on a retroactive basis as described in Note 10.

* 1,437,500 shares of common stock were issued to underwriter.

# 834,299 shares of common stock were issued to professional parties and board member.

See accompanying notes to the condensed consolidated financial statements.

Table of Contents

BIONEXUS GENE LAB CORP.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

	Nine months ended September 30,
	2023			2022
Cash flows from operating activities:
Net loss	$	(2,937,506	)	$	(198,997	)

Adjustments to reconcile net loss to net cash used in from operating activities:
Amortization of right of use asset		15,620			12,754
Allowances for expected credit losses		1,372,573			-
Bad debts		4,175			-
Depreciation of property, plant and equipment		63,147			66,608
Dividend income		(48,892	)		(34,523	)
Fair value (gain)/loss on other investments		(223,284	)		128,683
Loss on disposal of other investments		-			1,798
Interest		6,794			5,521
Property, plant and equipment written off		18			-
Share-base compensation		601,741			-
Stock written off		392			-
Operating loss before working capital changes		(1,145,222	)		(18,156	)

Changes in operating assets and liabilities:
Inventories		(130,502	)		425,972
Trade and other receivables		505,667			638,401
Deferred cost of revenue		-			67,606
Trade and other payables		(364,617	)		(769,436	)
Advance payment from customer		(14,905	)		(21,810	)
Deferred revenue		-			(77,276	)
Operating lease liabilities		81,989			(17,009	)
Tax recoverable		27,904			(153,209	)
Net cash (used in)/generated from operating activities		(1,039,686	)		75,083

Cash flows from investing activities:
Acquisition of other investment		(296,109	)		(397,974	)
Dividend income		48,892			34,523
Purchase of plant and equipment		(148,461	)		(37,144	)
Proceeds from disposal of other investments		26,854			-
Net cash used in investing activities		(368,824	)		(400,595	)

Cash flows from financing activities:
Interest		(6,794	)		(5,521	)
Repayment of finance lease		-			(34,038	)
Shares subscriptions		5,750,000			150,000
Net cash generated from financing activities		5,743,206			110,441
Foreign currency translation adjustment		(306,677	)		(446,579	)
NET CHANGE IN CASH AND CASH EQUIVALENTS		4,028,019			(661,650	)
CASH AND CASH EQUIVALENTS, BEGINNING OF FINANCIAL PERIOD		2,118,864			2,123,919

CASH AND CASH EQUIVALENTS, END OF FINANCIAL PERIOD	$	6,146,883		$	1,462,269

CASH AND CASH EQUIVALENTS INFORMATION:
Fixed deposits placed with financial institutions	$	1,442,098		$	984,088
Cash at bank		4,704,785			478,181
Cash and cash equivalents, end of financial period		6,146,883			1,462,269

Supplementary cash flow information:
Interest paid	$	(9,746	)	$	(7,717	)
Income tax refunded		315			-
Income taxes paid		(47,808	)		(123,599	)

See accompanying notes to the condensed consolidated financial statements.

Table of Contents

BIONEXUS GENE LAB CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

NOTE 1 – ORGANIZATION AND BUSINESS BACKGROUND

BioNexus Gene Lab Corp. (the “Company”) was incorporated in the State of Wyoming on May 12, 2017. On August 23, 2017, the Company acquired all the outstanding capital stock of Bionexus Gene Lab Sdn. Bhd., a Malaysian corporation (“BioNexus Malaysia”). BioNexus Malaysia was incorporated in Malaysia on April 7, 2015 which it then subsequently changed its name to MRNA Scientific Sdn. Bhd. (MRNA Scientific). on September 19, 2023.

The principal office address is Unit 02 Level 10, Tower B, Vertical Business Suite, No. 8 Jalan Kerinchi, Bangsar South, 59200 Kuala Lumpur, Malaysia, our lab is located at Lab 353, Chemical Science Centre, University Science Malaysia, George Town, Penang, Malaysia. We also have a blood collection center located at 1st floor, Lifecare Medical Centre, Kuala Lumpur, Malaysia.

On December 31, 2020, the Company consummated its acquisition of Chemrex Corporation Sdn. Bhd. (“Chemrex”), pursuant to a Share Exchange Agreement by and among the Company, Chemrex and the Chemrex shareholders wherein the Company acquired all the issued and outstanding shares of capital stock of Chemrex from the Chemrex shareholders in exchange for 68,487,261 shares of common stock of the Company.

The acquisition of Chemrex has been accounted for as a common control transaction as there is no change in the control over the assets acquired and liabilities assumed. The net assets are derecognized by the transferring entity (i.e. Chemrex) and recognized by the receiving entity (i.e. the Company). The difference between the consideration transferred and the carrying amounts of the net assets is recognized in equity.

The financial statements of the receiving entity report the results of operations for the period in which the transfer occurs as though the transfer of net assets or exchange of equity interests had occurred at the beginning of the period. Results of operations for that period will thus comprise those of the previously separate entities combined from the beginning of the period to the date the transfer is completed and those of the combined operations from that date to the end of the period. The comparative financial statements were not adjusted retrospectively as Chemrex was not under common control during the comparative period.

The corporate structure as at September 30, 2023 is depicted below:

	BioNexus Gene Lab Corp., a Wyoming company

100% owned		100% owned
MRNA Scientific Sdn. Bhd. (formerly “Bionexus Gene Lab Sdn. Bhd.”), a Malaysian company		Chemrex Corporation Sdn. Bhd., a Malaysian company

Table of Contents

BIONEXUS GENE LAB CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The accompanying unaudited condensed consolidated financial statements reflect the application of certain significant accounting policies as described in this note and elsewhere in the accompanying consolidated financial statements and notes.

·	Basis of presentation

The accompanying condensed consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”).

·	Basis of consolidation

The condensed consolidated financial statements include the accounts of Bionexus Gene Lab Corp. and its subsidiaries. All significant inter-company balances and transactions within the Company have been eliminated upon consolidation.

·	Use of estimates

In preparing these condensed consolidated financial statements, management makes estimates and assumptions that affect the reported amounts of assets and liabilities in the balance sheets and revenues and expenses during the periods reported. Actual results may differ from these estimates.

·	Cash and cash equivalents

Cash and cash equivalents represent cash on hand, demand deposits placed with banks or other financial institutions and all highly liquid investments with an original maturity of Three months or less as of the purchase date of such investments.

·	Trade receivables

Trade receivables were recorded at the invoiced amount and Chemrex did charge interest to certain debtors with overdue outstanding. Management reviews the adequacy of the allowance for impairment on an ongoing basis, using historical collection trends and aging of receivables. Management also periodically evaluates individual customer’s financial condition, credit history, and current economic conditions to adjust in the allowance when it is considered necessary. Trade balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.

·	Inventories

Inventories consisting of products available for sell are stated at the lower of cost or market value. Cost of inventory is determined using the first-in, first-out (FIFO) method. Inventory reserve is recorded to write down the cost of inventory to the estimated market value due to slow-moving merchandise and damaged goods, which is dependent upon factors such as historical and forecasted consumer demand, and promotional environment. The Company takes ownership, risks, and rewards of the products purchased. Write downs are recorded in cost of revenues in the Statement of Operations and Comprehensive Income.

Leases

Prior to January 1, 2019, the Company accounted for leases under ASC 840, Accounting for Leases. Effective January 1, 2019, the Company adopted the guidance of ASC 842, Leases, which requires an entity to recognize a right-of-use asset and a lease liability for virtually all leases. The Company adopted ASC 842 using a modified retrospective approach. As a result, the comparative financial information has not been updated and the required disclosures prior to the date of adoption have not been updated and continue to be reported under the accounting standards in effect for those periods.

Table of Contents

BIONEXUS GENE LAB CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

·	Property, plant and equipment

Property, plant and equipment are stated at cost less accumulated depreciation and accumulated impairment losses, if any. Depreciation is calculated on a straight-line basis to write off the cost over the following expected useful lives of the assets concerned.

The principal annual rates used are as follows:

Categories	Principal Annual Rates
Air conditioner		20	%
Buildings		2	%
Computer and software		33	%
Equipment		20	%
Furniture and fittings	10%to20%
Lab Equipment		10	%
Motor vehicle	10%to20%
Office equipment		20	%
Renovation	10%to20%
Signboard		10	%

Leasehold lands are depreciated over the period of the lease term. Leased assets are depreciated over the shorter of the lease term and their useful lives unless it is reasonably certain that the Company will obtain ownership by the end of the lease term. Freehold land is not depreciated. Property, plant and equipment under construction are not depreciated until the assets are ready for their intended use

Maintenance and repairs are charged to operations as incurred. Expenditures which substantially increase the useful lives of the related assets are capitalized. When properties are disposed, the related costs and accumulated depreciation are removed from the accounts and any gain or loss is reported in the period the transaction takes place.

Fully depreciated plant and equipment are retained in the financial statements until they are no longer in use.

Table of Contents

BIONEXUS GENE LAB CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

·	Impairment of long-lived assets

Long-lived assets primarily include goodwill, intangible assets and property, plant and equipment. In accordance with the provision of ASC Topic 360, “Impairment or Disposal of Long-Lived Assets,” the Company generally conducts its annual impairment evaluation to its long-lived assets, usually in the fourth quarter of each fiscal year, or more frequently if indicators of impairment exist, such as a significant, sustained change in the business climate. The recoverability of long-lived assets is measured at the lowest level group. If the total of the expected undiscounted future net cash flows is less than the carrying amount of the asset, a loss is recognized for the difference between the fair value and carrying amount of the asset. There has been no impairment charge for the years presented.

·	Revenue recognition

Revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services.

The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements:

·	identify the contract with a customer;
·	identify the performance obligations in the contract;
·	determine the transaction price;
·	allocate the transaction price to performance obligations in the contract; and
·	recognize revenue as the performance obligation is satisfied.

The Company records revenue at point in time which is recognized upon goods delivered or services rendered.

·	Shipping and handling fees

Shipping and handling fees, if billed to customers, are included in revenue. Shipping and handling fees associated with inbound and outbound freight are expensed as incurred and included in selling and distribution expenses.

Table of Contents

BIONEXUS GENE LAB CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

·	Comprehensive income

ASC Topic 220, “Comprehensive Income” establishes standards for reporting and display of comprehensive income, its components and accumulated balances. Comprehensive income as defined includes all changes in equity during a period from non-owner sources. Accumulated other comprehensive income, as presented in the accompanying statements of stockholders’ equity consists of changes in unrealized gains and losses on foreign currency translation and cumulative net change in the fair value of available-for-sale investments held at the balance sheet date. This comprehensive income is not included in the computation of income tax expense or benefit.

·	Income taxes

Income taxes are determined in accordance with the provisions of ASC Topic 740, “Income Taxes” (“ASC Topic 740”). Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Any effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

ASC 740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclosed in their financial statements uncertain tax positions taken or expected to be taken on a tax return. Under ASC 740, tax positions must initially be recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions must initially and subsequently be measured as the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and relevant facts.

The Company conducts major businesses in Malaysia and is subject to tax in their own jurisdictions. As a result of its business activities, the Company will file separate tax returns that are subject to examination by the foreign tax authorities.

·	Net earnings or loss per share

The Company calculates net earnings or loss per share in accordance with ASC Topic 260 “Earnings per share.” Basic earnings or loss per share is computed by dividing the net earnings or loss by the weighted average number of common shares outstanding during the period. Diluted earnings or loss per share is computed similar to basic earnings or loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common stock equivalents had been issued and if the additional common shares were dilutive.

Table of Contents

BIONEXUS GENE LAB CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

·	Foreign currencies translation

Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the statement of operations.

The functional currency of the Company is the United States Dollars (“US$”) and the accompanying financial statements have been expressed in US$. In addition, the subsidiaries maintain their books and records in a local currency, Malaysian Ringgit (“MYR” or “RM”), which is functional currency as being the primary currency of the economic environment in which the subsidiaries operate.

In general, for consolidation purposes, assets and liabilities of its subsidiaries whose functional currency is not US$ are translated into US$, in accordance with ASC Topic 830-30, “Translation of Financial Statement,” using the exchange rate on the balance sheet date. Revenues and expenses are translated at average rates prevailing during the period. The gains and losses resulting from the translation of financial statements of foreign subsidiaries are recorded as a separate component of accumulated other comprehensive income.

Translation of amounts from MYR into US$1.00 has been made at the following exchange rates for the respective period and year:

	September 30,		December 31,
	2023		2022
Period ended September 30, 2023 /Year-ended December 31, 2022 US$1: MYR exchange rate		4.6920		4.3900

	January 1, 2023 to September 30, 2023		January 1, 2022 to September 30, 2022
9 months average US$1: MYR exchange rate		4.5192		4.3442

·	Related parties

Parties, which can be a corporation or individual, are considered to be related if the Company has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Companies are also considered to be related if they are subject to common control or common significant influence.

Table of Contents

BIONEXUS GENE LAB CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

☐	Fair value of financial instruments

The carrying value of the Company’s financial instruments: cash and cash equivalents, trade receivable, deposits and other receivables, amount due to related parties and other payables approximate at their fair values because of the short-term nature of these financial instruments.

The Company also follows the guidance of the ASC Topic 820-10, “Fair Value Measurements and Disclosures” (“ASC 820-10”), with respect to financial assets and liabilities that are measured at fair value. ASC 820-10 establishes a six-tier fair value hierarchy that prioritizes the inputs used in measuring fair value as follows:

☐	Level 1 : Observable inputs such as quoted prices in active markets;

☐	Level 2 : Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

☐	Level 3 : Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions

As of September 30, 2023, and December 31, 2022, the Company did not have any nonfinancial assets and liabilities that are recognized or disclosed at fair value in the financial statements, at least annually, on a recurring basis, nor did the Company have any assets or liabilities measured at fair value on a non-recurring basis.

☐	Recent accounting pronouncements

The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and do not believe the future adoption of any such pronouncements may be expected to cause a material impact on its financial condition or the results of its operations.

☐	Recently Adopted Accounting Standards

In June 2016, the FASB issued Accounting Standards Update No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which introduced the expected credit losses methodology for the measurement of credit losses on financial assets measured at amortized cost basis, replacing the previous incurred loss methodology. In November 2019, the FASB issued ASU 2019-10 highlighted the adoption timeline. For smaller reporting entities, Topic 326 is effective for annual periods beginning after December 15, 2022, including interim periods within those fiscal years, of which is effective for the Company on January 1, 2023

Credit loss rate is determined by historical collection based on aging schedule, adjusted for current conditions using reasonable and supportable forecasts. Based on the aging categorization and the adjusted loss rate per category, an allowance for credit losses is calculated by multiplying the adjusted loss rate with the amortized cost in the respective age category.

NOTE 3 - TRADE RECEIVABLES

The Company has performed an analysis on all its trade receivables. As such, trade receivables are recognized and carried at the original invoice amount less an allowance for any uncollectible amounts. An estimate for doubtful debts and expected credit losses is made when collection of the full amount is no longer probable. Bad debts are written off as identified for the quarter ended September 30, 2023. The Company’s trade receivables consist of receivable from customers which are unrelated to the Company. The account receivables are interest bearing at a rate of 6% per annum on Interlink Techno started in May 2021 till June 2023. From July 2023 onwards, Chemrex had increased the interest to 8.4%. Chemrex imposed 6% per annum interest on Mawintech Sdn Bhd since May 2021 till to date. The normal trade credit term is generally on 30 days to 90 days term.

	As of
	September 30,			December 31,
	2023			2022

Trade receivables		2,222,414			2,868,364
Allowances for expected credit losses		(1,322,018	)		-
	$	900,396		$	2,868,364

Table of Contents

BIONEXUS GENE LAB CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

NOTE 4 - INCOME TAXES

The Company provides for income taxes under ASC 740, “Income Taxes. ASC 740 requires the use of an asset and liability approach in accounting for income taxes. Deferred tax assets and liabilities are recorded based on the differences between the financial statements and tax basis of assets and liabilities and the tax rates in effect when these differences are expected to reverse. It also requires the reduction of deferred tax assets by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.

Provision for income taxes consisted of the following:

United States of America

The Company is registered in the State of Wyoming and is subject to the tax laws of the United States of America.

Malaysia

MRNA Scientific Malaysia and Chemrex are both subject to Malaysia Corporate Tax, which is charged at the statutory income tax rate range of 24% on its assessable income.

	As of
	September 30,			December 31,
	2023			2022
Tax Recoverable
Local	$	-		$	-
Foreign, representing Malaysia		(3,838	)		(31,551	)
Tax Recoverable		(3,838	)		(31,551	)

Income tax liabilities:
Local	$	-		$	-
Foreign, representing Malaysia		2,177			-
Income tax payables		2,177			-

Deferred tax liabilities:
Local	$	-		$	-
Foreign, representing Malaysia		28,880			30,866
Deferred tax liabilities		28,880			30,866
Total		27,219			(685	)

Table of Contents

BIONEXUS GENE LAB CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

NOTE 5 – OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES

Right-of-use assets and lease liabilities are measured at present value of the lease payment over the lease term as of recognition with discount rate of 6.40% per annum effective date and 6.65% per annum effective date initial recognized date adopted from Malayan Banking (Maybank) Berhad's base rate as a reference for the discount rate, as this bank is the largest bank and national bank of Malaysia.

A single lease cost is recognized over the lease term on a generally straight-line basis. All cash payments of operating lease costs are classified within operating activities in the statement of cash flows.

Operating lease right of use assets as follows:	As of
	September 30,			December 31,
	2023			2022
Balance as of beginning of the period/year	$	55,730		$	41,090
Add: Addition of lease liabilities		110,817			32,281
Less: Amortization		(15,045	)		(15,534	)
Foreign translation differences		(3,586	)		(2,107	)
Balance as of end of the period/year	$	147,916		$	55,730

Operating lease liabilities as follows:
	September 30,			December 31,
	2023			2022
Balance as of beginning of the period/year	$	56,775		$	42,909
Add: Addition of lease liabilities		110,817			30,770
Less: gross repayment		(28,485	)		(19,618	)
Add: imputed interest		3,311			4,913
Foreign translation differences		(3,654	)		(2,199	)
Balance as of end of the year		138,764			56,775
Less: lease liability current portion		(33,897	)		(16,569	)
Lease liability non-current portion	$	104,867		$	40,206

The amortization of the right of use asset for the nine months’ period ended September 30, 2023 and nine months’ period ended September 30, 2022 were $15,620 and $12,754 respectively.

Other information:	As of
	September 30, 2023			December 31, 2022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flow from operating lease	$	81,989		$	(126,686	)
Right of use assets obtained in exchange for operating lease liabilities		147,916			55,730
Remaining lease term for operating lease (years)		4.75			4
Weighted average discount rate for operating lease	$	6.53	%	$	6.40	%

Lease expenses for the nine months’ period ended September 30, 2023 and nine months’ period ended September 30, 2022 were $3,438 and $1,358, respectively.

Table of Contents

BIONEXUS GENE LAB CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

NOTE 6 - PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment consisted of the following:

	As of
	September 30,			December 31,
	2023			2022
Air conditioner	$	1,124		$	1,124
Computer and software		2,516			2,516
Equipment		59,801			60,525
Furniture and fittings		100,118			87,122
Lab equipment		430,742			320,102
Land and buildings		1,506,969			1,506,969
Motor vehicle		161,148			137,914
Office equipment		33,477			38,213
Renovation		98,597			107,414
Signboard		806			704
		2,395,298			2,262,603
(Less): Accumulated depreciation		(638,363	)		(590,317	)
Add: Foreign translation differences		(260,373	)		(160,578	)
Property, plant and equipment, net	$	1,496,562		$	1,511,708

Depreciation expense for the nine months’ period ended September 30, 2023 and 2022 were $63,147 and $66,608 respectively.

NOTE 7 - OTHER INVESTMENTS

	As of
	September 30,			December 31,
	2023			2022
As of beginning of the period/year	$	1,150,898		$	749,027
Addition during the period/year		296,109			511,706
Disposal during the period/year		(26,854	)		-
Written off during the period/year		-			(1,776	)
Fair value gain/(loss)		223,284			(70,628	)
Foreign exchange translation		(92,220	)		(37,431	)
As of end of the period/year	$	1,551,217		$	1,150,898

The other investments consist of the following shares:
	As of
	September 30,		December 31,
	2023		2022
Investment in quoted shares:
Malaysia		982,257		659,970
Singapore		84,407		101,426
Hong Kong		484,553		389,502
	$	1,551,217	$	1,150,898

NOTE 8 - TRADE PAYABLES

Trade payables are amounts billed to the Company by suppliers for goods and services in the ordinary course of business. All amounts have short-term repayment terms and vary by supplier.

Table of Contents

BIONEXUS GENE LAB CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

NOTE 9 - CONCENTRATION OF RISKS

a) Major customers

During the three months and nine months ended September 30, 2023 and 2022, the Company did not have any material recognizable major customers accounted for 10% or more of the Company’s revenue.

b) Major suppliers

For three months ended September 30, 2023 and 2022, the suppliers who accounted for 10% or more of the Company’s cost of sales and their balances at year ended are presented as follows:

	2023		2022		2023			2022			2023		2022
	Purchase				Percentage of purchases						Accounts payable trade
Vendor A	$	407,094	$	268,101		18.51	%		11.78	%	$	467,447	$	256,536
Vendor B	$	353,697	$	233,770		16.08	%		10.27	%	$	279,092	$	227,124
Vendor C	$	320,413	$	282,848		14.57	%		12.43	%	$	316,067	$	272,734
	$	1,081,204	$	784,719		49.16	%		34.48	%	$	1,062,606	$	756,394

For nine months ended September 30, 2023 and 2022, the suppliers who accounted for 10% or more of the Company’s cost of sales and their balances at year ended are presented as follows:

	2023		2022		2023			2022			2023		2022
	Purchase				Percentage of purchases						Accounts payable trade
Vendor A	$	1,167,862	$	1,012,770		18.15	%		14.13	%	$	316,067	$	272,734
Vendor B	$	1,077,986	$	924,246		16.75	%		12.89	%	$	467,447	$	256,536
Vendor C	$	922,895	$	815,818		14.34	%		11.38	%	$	279,092	$	227,124
	$	3,168,743	$	2,752,834		49.24	%		38.40	%	$	1,062,606	$	756,394

NOTE 10 - STOCK HOLDERS’ EQUITY

Reverse Stock Split

On June 5, 2023, the Company filed an Article of Amendment to the Articles of Incorporation with the Wyoming Secretary of State to modify the ratio of the Reverse Stock Split from one-for-ten (10) to one-for-twelve (12) (the “Revised Reverse Stock Split”). Upon effectiveness of the Revised Reverse Stock Split, every twelve (12) outstanding shares of common stock were combined into and automatically became one share of common stock. No fractional shares was issued in connection with the Revised Reverse Stock Split and all such fractional shares or odd lots (less than 100 shares to any record or beneficial holder) issuable in the Revised Reverse Stock Split were rounded up to 100 shares. An aggregate of 1,044,351 shares were issued to applicable shareholders as a result of the round-up.

The Revised Reverse Stock Split was approved and authorized by a majority of the Company’s stockholder on May 8, 2023 and by the Board of Directors of the Company on May 8, 2023.

Public Offering & Nasdaq Listing

On July 20, 2023, the Company entered into an underwriting agreement (the "Underwriting Agreement") with Network 1 Financial Securities, Inc., as underwriter (the "Underwriter") pursuant to which the Company agreed to issue and sell, in a firm commitment underwritten public offering by the Company (the "Offering") of 1,250,000 shares of common stock, no par value, priced at a public offering price of $4.00 per share.

In addition, pursuant to the Underwriting Agreement, the Underwriter was granted a 45-day option (the "Over-Allotment Option") to purchase up to an additional 187,500 shares of common stock at the public offering price of $4.00 per share. The Underwriter fully exercised the Over-Allotment Option on July 24, 2023.

The securities were offered by the Company pursuant to the registration statement on Form S-1 (File No. 333-269753), which was originally filed with the U.S. Securities and Exchange Commission (the "Commission") under the Securities Act of 1933, as amended, on February 14, 2023, and declared effective by the Commission on July 19, 2023.

On July 24, 2023, the Offering closed, and the Company issued and sold 1,437,500 shares of common stock, including 187,500 shares sold pursuant to the full exercise of the Over-Allotment Option. The Offering was priced at $4.00 per share for total gross proceeds of $5.75 million before deducting underwriting discounts, commissions, and offering expenses. Pursuant to the Underwriting Agreement, the Underwriter received an 8% underwriting discount on the public offering price for the shares common stock. The Company will therefore receive net proceeds, before expenses, of $5,290,000 from the sale of the common stocks. In addition, the Company issued to the Underwriter warrants to purchase up to an aggregate of 115,000 shares of the Company's common stock (the "Underwriter's Warrants") at an exercise price of $4.40 per share. The Underwriter's Warrants are exercisable from July 24, 2023 until July 24, 2028.

In August, 2023, an aggregate of 759,299 shares of common stock were issued to professional parties or service providers in lieu of cash for services rendered, 125,000 were subsequently cancelled in November, 2023.

In August, 2023, an aggregate of 75,000 shares of common stock were issued to three directors in lieu of cash for services rendered in connection with their employment as directors of the Company.

From July 20, 2023 to August 4, 2023, an aggregate total of 1,044,351 shares of common stock were issued as part of the round-up exercise to the reverse stock split.

Table of Contents

BIONEXUS GENE LAB CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

NOTE 11 – SEGMENTED INFORMATION

At September 30, 2023, the Company (“BGLC”) operates in the biochemical industry segment through its two Malaysian subsidiaries, MRNA Scientific Malaysia (formerly known as Bionexus Gene Lab Sdn. Bhd.) and Chemrex.

	BioNexus Gene Lab Corp., a Wyoming company

100% owned		100% owned
MRNA Scientific Sdn. Bhd. (formerly “Bionexus Gene Lab Sdn. Bhd.”), a Malaysian company		Chemrex Corporation Sdn. Bhd., a Malaysian company

At September 30, 2023, the Company (“BGLC”) operates in the biochemical industry segment through its two Malaysian subsidiaries, MRNA Scientific Malaysia and Chemrex.

For the nine months ended September 30, 2023, segmented (unaudited) revenue and net profit/(loss) (Currency expressed in United States Dollars (“US$”) are as follows:

	MRNA Scientific Malaysia			Chemrex			BGLC			Total
	Nine months ended September 30, 2023

REVENUE	$	28,468		$	7,469,271		$	-		$	7,497,739

COST OF REVENUE		(14,849	)		(6,419,947	)		-			(6,434,796	)

GROSS PROFIT		13,619			1,049,324			-			1,062,943

OTHER INCOME		3,922			507,870			-			511,792

OPERATING EXPENSES
General and administrative		(170,590	)		(2,348,127	)		(1,907,360	)		(4,426,077	)

LOSS FROM OPERATIONS		(153,049	)		(790,933	)		(1,907,360	)		(2,851,342	)

FINANCE COSTS		(2,952	)		(6,794	)		-			(9,746	)

LOSS BEFORE TAX		(156,001	)		(797,727	)		(1,907,360	)		(2,861,088	)

Tax expense		-			(76,418	)		-			(76,418	)

NET LOSS	$	(156,001	)	$	(874,145	)	$	(1,907,360	)	$	(2,937,506	)

Table of Contents

BIONEXUS GENE LAB CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

	MRNA Scientific Malaysia			Chemrex			BGLC			Total
	Nine months ended September 30, 2022
REVENUE	$	39,409		$	8,049,723		$	-		$	8,089,132

COST OF REVENUE		(19,173	)		(7,150,156	)		-			(7,169,329	)

GROSS PROFIT		20,236			899,567			-			919,803

OTHER INCOME		6,617			146,720			3			153,340

OPERATING EXPENSES
General and administrative		(157,686	)		(906,698	)		(177,247	)		(1,241,631	)

(LOSS)/PROFIT FROM OPERATIONS		(130,833	)		139,589			(177,244	)		(168,488	)

FINANCE COSTS		(2,196	)		(5,521	)		-			(7,717	)

(LOSS)/PROFIT BEFORE TAX		(133,029	)		134,068			(177,244	)		(176,205	)

Tax expense		-			(22,792	)		-			(22,792	)

(LOSS)/PROFIT AFTER TAX	$	(133,029	)	$	111,276		$	(177,244	)	$	(198,997	)

Table of Contents

BIONEXUS GENE LAB CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

	As of September 30, 2023 and December 31, 2022
	Total Assets				Total Liabilities
	2023		2022		2023		2022

BGLC & MRNA Scientific	$	5,002,908	$	677,477	$	176,805	$	108,390
Chemrex		6,462,614		8,062,685		1,601,002		1,966,759
TOTAL		11,465,522		8,740,162		1,777,807		2,075,149

NOTE 12 – SUBSEQUENT EVENTS

In accordance with ASC Topic 855, “Subsequent Events,” which establishes general standards of accounting for and disclosure of events that occur after the balance sheet date but before financial statements are issued, the Company has evaluated all events or transactions that occurred after September 30, 2023 up through November 20, 2023 of these consolidated financial statements.

On August 1, 2023, Mr. Liong Tai Tan, the Chief Operating Officer and a member of the Board of Directors, notified the Company of his desire to resign from his position at the Company. The Company and Mr. Liong Tai Tan agreed that the resignations would be effective August 31, 2023. Mr. Liong Tai Tan’s resignation is not due to any disagreement with the Company, the Company’s management or the Board on any matter relating to the Company’s operations, policies, or practices (financial or otherwise), Mr. Liong Tai Tan informed the Company that he is leaving the Company and the Board of Directors to pursue other commitments. On August 2, 2023, the Board of Directors of the Company approved the appointment of Mr. Su-Leng Tan Lee as the Chief Operating Officer and not a director, effective September 1, 2023.

On October 4, 2023, Mr. Sook Keng Yeoh, the Chief Executive Officer and a member of the Board of Directors, tendered his resignation letter to the Company from his positions at the Company. The Company and Mr. Sook Keng Yeoh agreed that the resignations would be effective October 4, 2023. Mr. Sook Keng Yeoh’s resignation is not due to any disagreement with the Company, the Company’s management, or the Board on any matter relating to the Company’s operations, policies, or practices (financial or otherwise). On October 12, 2023, the board of directors of the Bionexus Gene Lab Corp. (“the Company”) approved the appointment of Mr. Chi Yuen Leong as the Chief Executive Officer and a director, effective October 12, 2023. Mr. Leong has a family relationship with the Company’s outgoing CFO, Wei Li Leong. Ms. Wei Li Leong is the daughter of Mr. Leong.

On October 30, 2023, Ms. Wei Li Leong, the Chief Financial Officer (“CFO”), tendered her resignation letter to the Company from her position at the Company. The Company and Ms. Leong agreed that the resignation would be effective October 30, 2023 (“Resignation Date”), and Ms. Leong agreed to continue serving for one additional month from the Resignation Date. Ms. Leong’s resignation is not due to any disagreement with the Company, the Company’s management, or the Board on any matter relating to the Company’s operations, policies, or practices (financial or otherwise). The Company will actively identify a replacement personnel. The Company believes that it will be able to appoint a new CFO in the near future.

On December 11, 2023, a majority of shareholders executed a Written Consent to Action Without Meeting of the Shareholders (the “Written Consent”) removing the certain Board members and appointing three new board members of the shareholders’ choosing. This was subsequently notified via a Schedule 14C mailer to all eligible shareholders, on or about 5^th March 2024.

The New Directors began serving their term on December 11, 2023, and their terms shall expire at our annual meeting of stockholders to be held in 2024.

Additionally, by unanimous written consent effective December 11, 2023, the Board appointed Su-Leng Tan Lee and Chee Keong Yap to the Board, and Mr. Su-Leng Tan Lee to serve as Chief Executive Officer and Secretary to the Board, effective December 11, 2023.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Description of Business

As used herein, unless the context otherwise indicates, references to the “Company,” “we,” “our,” “us,” “BioNexus” refer to BioNexus Gene Lab Corp., a Wyoming company (“BGLC”), and its wholly owned subsidiaries, MRNA Scientific Sdn. Bhd. (“MRNA Scientific Malaysia”), and Chemrex Corporation Sdn. Bhd. (“Chemrex”), both are Malaysian companies.

BGLC is an emerging molecular lab focused on the application of functional genomics to enable early detection of infectious diseases and cancers. On August 23, 2017, we acquired all of the outstanding capital stock of MRNA Scientific Malaysia, which was incorporated in Malaysia on April 7, 2015. MRNA Scientific Malaysia owns algorithm software, technology, and know-how related to the detection of common diseases through blood analysis which we use in our business. Our non-invasive blood screening tests analyze changes in ribonucleic acid (or RNA) to Coronavirus, Dengue, HIV, HPV and the risk potentiality of cancers diseases. This unique blood genomic biomarker approach is based on the scientific observation that circulating blood reflects, in a detectable way, what is occurring throughout the body currently.

The corporate and principal office address of the Company and MRNA Scientific Malaysia is Unit 02, Level 10, Tower B, Avenue 3, The Vertical Business Suite II, Bangsar South, No. 8 Jalan Kerinchi, Kuala Lumpur, Malaysia., our lab is located at Lab 353, Chemical Science Centre, University Science Malaysia, George Town, Penang, Malaysia. Another lab focuses on Covid-19 and Colon cancer screening is located at 4th floor, Lifecare Diagnostic Centre, Kuala Lumpur, Malaysia. Our telephone number is (+60) 18-2218762 and our website is www.bionexusgenelab.com.

Chemrex is a wholesaler of industrial chemicals for the manufacture of industrial, medical, appliance, aero, automotive, mechanical and electronic industries in Asean region. On December 31, 2020, we acquired all of the outstanding capital stock of Chemrex, which was incorporated in Malaysia on September 29, 2004.

Chemrex’s corporate office and distribution and storage center is located at 4 Jalan CJ 1/6 Kawasan Perusahaan Cheras Jaya, Selangor, Malaysia. Its phone number is (+60) 1922-23815 and website is www.chemrex.com.my.

Table of Contents

The results of operations of our subsidiary, MRNA Scientific-Malaysia , with respect to its RNA screening process have been adversely impacted by the onset of the Covid-19 pandemic followed by a number of prominent variants, including Alpha, Beta, Delta, and Omicron. Although new variants are an expected part of the evolution of viruses, new variant is more aggressive, highly transmissible, vaccine-resistant, able to cause more severe disease in Malaysia. We believe that most people were reluctant to visit hospitals and clinics in view of the post Covid-19 Omicron and its subvariants for fear of transmission from other patients or medical staff. Since our RNA screening is administered at a diagnostic center, our business has been adversely affected as a result.

The results of operations for Chemrex were adversely impacted during fiscal year 2023 and the 1^st quarter of 2023 as businesses of Chemrex customers especially the manufacturers had suffered significant impact. Many of them across the country saw their supply chains interrupted, demand for their products and services decline, shortages in supplies and inputs.

Recent Developments.

(i) Public Offering and Nasdaq Listing

On July 20, 2023, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Network 1 Financial Securities, Inc., as underwriter (the “Underwriter”) pursuant to which the Company agreed to issue and sell, in a firm commitment underwritten public offering by the Company (the “Offering”) of 1,250,000 shares of common stock, no par value, priced at a public offering price of $4.00 per share.

In addition, pursuant to the Underwriting Agreement, the Underwriter was granted a 45-day option (the “Over-Allotment Option”) to purchase up to an additional 187,500 shares of common stock at the public offering price of $4.00 per share. The Underwriter fully exercised the Over-Allotment Option on July 24, 2023.

The securities were offered by the Company pursuant to the registration statement on Form S-1 (File No. 333-269753), which was originally filed with the U.S. Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended, on February 14, 2023, and declared effective by the Commission on July 19, 2023.

On July 24, 2023, the Offering closed, and the Company issued and sold 1,437,500 shares of common stock, including 187,500 shares sold pursuant to the exercise of the Over-Allotment Option. The Offering was priced at $4.00 per share for total gross proceeds of $5.75 million before deducting underwriting discounts, commissions, and offering expenses. Pursuant to the Underwriting Agreement, the Underwriter received an 8% underwriting discount on the public offering price for the shares common stock. The Company will therefore receive net proceeds, before expenses, of $5,290,000 from the sale of the common stocks. In addition, the Company issued to the Underwriter warrants to purchase up to an aggregate of 115,000 shares of the Company’s common stock (the “Underwriter’s Warrants”) at an exercise price of $4.40 per share. The Underwriter’s Warrants are exercisable from July 24, 2023 until July 24, 2028.

On August 2023, there was an issuance of shares of 759,299 and 75,000 respectively as part of Contractual Agreements relating to the uplisting of our Common Stock onto the NASDAQ stock exchange, subsequently followed by the cancellation of 125,000 shares. Please see Note 10.

(b) Reverse stock split

On June 5, 2023, the Company filed an Article of Amendment to the Articles of Incorporation with the Wyoming Secretary of State to modify the ratio of the Reverse Stock Split from one-for-ten (10) to one-for-twelve (12) (the “Revised Reverse Stock Split”). Upon effectiveness of the Revised Reverse Stock Split, every twelve (12) outstanding shares of common stock were combined into and automatically become one share of common stock. No fractional shares were issued in connection with the Revised Reverse Stock Split and all such fractional shares or odd lots (less than 100 shares to any record or beneficial holder) issuable in the Revised Reverse Stock Split were rounded up to 100 shares.

The Revised Reverse Stock Split was approved and authorized by a majority of the Company’s stockholder on May 8, 2023 and by the Board of Directors of the Company on May 8, 2023.

On July 19, 2023, the Financial Industry Regulatory Authority announced the Revised Reverse Stock Split.in conjunction with the aforementioned Nasdaq listing.

An total of 1,044,351 round-up shares issued after reversal of stock split exercised. Please refer Note 10.

Translation of amounts from MYR into US$1.00 has been made at the following exchange rates for the respective period and year:

	September 30,		December 31,
	2023		2022
Period ended September 30, 2023 /Year-ended December 31, 2022 US$1: MYR exchange rate		4.6920		4.3900

	January 1, 2023 to September 30, 2023		January 1, 2022 to September 30, 2022
9 months average US$1: MYR exchange rate		4.5192		4.3442

Table of Contents

Results of Operations

Three Months Ended September 30, 2023 Compared with the Three Months Ended September 30, 2022.

The following table sets forth key selected financial data for the three months ended September 30, 2023 and 2022.

Consolidated

	Three months ended
	September 30,
	2023			2022
REVENUE	$	2,553,686		$	2,575,086

COST OF REVENUE		(2,199,354	)		(2,275,587	)

GROSS PROFIT		354,332			299,499

OTHER INCOME		199,284			54,110

OPERATING EXPENSES
General and administrative		(3,082,128	)		(418,824	)

LOSS FROM OPERATIONS		(2,528,512	)		(65,215	)

FINANCE COSTS		(4,259	)		(2,072	)

LOSS BEFORE TAX		(2,532,771	)		(67,287	)

Tax expense		(76,418	)		(10,114	)

NET LOSS	$	(2,609,189	)	$	(77,401	)
Other comprehensive income:
Foreign currency loss		(18,603	)		(320,592	)

COMPREHENSIVE LOSS	$	(2,627,792	)	$	(397,993	)

Table of Contents

Segmented Information

	MRNA Scientific Malaysia			Chemrex			MRNA Scientific Malaysia			Chemrex
	Three months ended September 30, 2023						Three months ended September 30, 2022
REVENUE	$	16,536		$	2,537,150		$	5,942		$	2,569,144

COST OF REVENUE		(7,301	)		(2,192,053	)		(4,244	)		(2,271,343	)

GROSS PROFIT		9,235			345,097			1,698			297,801

OTHER INCOME		1,757			197,527			2,332			51,775

OPERATING EXPENSES
General and administrative		(71,870	)		(1,322,231	)		(63,005	)		(288,350	)

(LOSS)/PROFIT FROM OPERATIONS		(60,878	)		(779,607	)		(58,975	)		61,226

FINANCE COSTS		(1,677	)		(2,582	)		(336	)		(1,736	)

(LOSS)/PROFIT BEFORE TAX		(62,555	)		(782,189	)		(59,311	)		59,490

Tax expense		-			(76,418	)		-			(10,114	)

NET (LOSS)/PROFIT	$	(62,555	)	$	(858,607	)	$	(59,311	)	$	49,376

Revenue. For the quarter ended September 30, 2023, we had total revenue of $2,553,686 as compared to total revenue of $2,575,086 for the quarter ended September 30, 2022, decreased by 0.8% from the prior quarter due to slight decrease in purchases from customers.

Chemrex contributed $2,537,150 (99.4%) of the total revenue for the current quarter ended September 30, 2023 as compared to $2,569,144 (99.8%) of the total revenue for the quarter ended September 30, 2022. Chemrex’s revenues had the decrease of 1.2% from prior quarter. The revenue decreased in third quarter of 2023 was due to decrease in purchases from customers as no new project in market

MRNA Scientific-Malaysia contributed $16,536 (0.6%) of the total revenue for the quarter ended September 30, 2023 as compared to revenue of $5,942 (0.2%) of the total revenue from the quarter ended September 30, 2022. Revenues had increased by $10,594 from prior quarter of $5,942, a 178.3% increase due to RNA test from BGLC shareholders.

Cost of Revenue. For the quarter ended September 30, 2023, we incurred $2,199,354 in cost of revenues, as compared to $2,275,587 for the quarter ended September 30, 2022, a slight decrease of 3.4% was due to reason as stated above.

Chemrex had incurred $2,192,053 (99.7%) of the total cost of revenue during the current quarter period ended September 30, 2023 as compared to the quarter ended September 30, 2022 wherein Chemrex had incurred $2,271,343 (99.8%) of the total cost of revenue. The slightly decrease in Chemrex’s cost of revenues of 3.5% for the current period was due to its decreased revenues, stock price reduced and reason as stated above.

MRNA Scientific-Malaysia had incurred $7,301 (0.3%) of the total cost of revenues during the current quarter period ended September 30, 2023 as compared to $4,244 (0.2%) for the quarterly period ended September 30, 2022. Cost of revenue had increased by $3,057 from prior quarter of 72% increase was due to its increased revenues and reason as stated above.

Table of Contents

Gross Profit. For the quarterly period ended September 30, 2023, we had total gross profit of $354,332 as compared to gross profit of $299,499 for the quarterly period ended September 30, 2022, an increase by approximately 18.3% from the prior period.

Chemrex contributed $345,097 (97.4%) of the total gross profit for the current quarter ended September 30, 2023 as compared to $297,801 (99.4%) of the total gross profit for the quarter ended September 30, 2022. Chemrex’s gross profit increased by $47,296 from the prior quarter, an approximately 15.9% increase. The gross profit increase for Chemrex in current quarter was due to old stock at lower prices.

MRNA Scientific-Malaysia contributed $9,235 (2.6%) of the total gross profit of $354,332 for the current quarter ended September 30, 2023 as compared to gross profit of $1,698 (0.6%) of the total gross profit from the quarter ended September 30, 2022. The increase of $7,537 by approximately 443.9% from the prior period due to its increased revenues for the same reason stated above.

Other Income. For the quarterly period ended September 30, 2023, we had of $199,284, as compared to of $54,110 for the quarterly period ended September 30, 2022, an increase of approximately 268.3%.

Chemrex contributed $197,527 (99.1%) of other income for the current quarter ended September 30, 2023 as compared to $51,775 (95.7%) of the other income for the quarter ended September 30, 2022. Chemrex’s other income increased by 281.5% due to dividend received, gain on fair value of investment, bank interest earning and unrealized equity investment gain.

MRNA Scientific-Malaysia contributed $1,757 (0.9%) of other income for the current quarter ended September 30, 2023 as compared to $2,332 (4.3%) of the other income for the quarter ended September 30, 2022. The decrease of 24.7% due to lesser fund in the fixed deposit resulted from a reduction in bank interest earning.

Operating Expenses. For the quarter ended September 30, 2023, we had total operating expense of $3,082,128 as compared to total operating expenses of $418,824 for the quarter ended September 30, 2022, an increase by approximately 635.9%. It was due to general and administrative expenses which includes depreciation of fixed assets, employee compensation, professional fees for the Nasdaq uplisting and provision for losses on accounts receivable

Chemrex had incurred $1,322,231 (42.9%) of the total operating expenses for the current quarter ended September 30, 2023 as compared to $288,350 (68.8%) of the total operating expenses for the quarter ended September 30, 2022, an increase by 358.6.%. The major increase in operating expenses was due to provision for losses on accounts receivable of $1,067,413

MRNA Scientific-Malaysia had incurred $71,870 (2.3%) of the total operating expenses for the current quarter ended September 30, 2023 as compared to $63,005 (15%) of the total operating expenses for the quarter ended September 30, 2022, an increase by 14.1%. The increase in operating costs of the current quarter was due to hire new staff, increment of staff remuneration, increase of depreciation of fixed assets for new lab equipment and motor vehicle and additional cost for motor vehicle running expenses and travelling expenses.

BGLC, the holding company had incurred $1,688,027 (54.8%) of total operating expenses for the current quarter ended September 30, 2023 as compared to $67,469 (16.1%) of the total operating expenses for the quarter ended September 30, 2022. The increase of $1,620,558 by approximately 2401.9% in operating costs for the quarter ended September 30, 2023 was due to increment of directors ’ fees, hired a medical adviser, appointed an investor relations service, additional professional expenses for successful listed in Nasdaq from Advisor, Attorney, underwriting cost expenses, share-based compensation, broker fee, NOBO conduit fee, listing expenses and Nasdaq annual fee.

Loss from Operations. We had a loss from operations of $2,528,512 for the quarter ended September 30, 2023 as compared to a loss of $65,215 for the quarter ended September 30, 2022, an increase by approximately 3777.2% from the prior period, for the reasons was due to increment of directors ’ fees, hired a medical adviser, appointed an investor relations service, additional professional expenses for successful listed in Nasdaq from Advisor, Attorney, underwriting cost expenses, share-based compensation, broker fee, conduit fee, listing expenses and Nasdaq annual fee.

Income tax expense. For the quarter ended September 30, 2023, we had a tax expense of $76,418 as compared to tax expenses of $10,114 for the quarter ended September 30, 2022 for Chemrex. There was no tax provision for MRNA Scientific-Malaysia for the quarters ended September 30, 2023 and 2022.

Foreign currency exchange loss. We are exposed to fluctuations in foreign exchange rates on the revaluation of monetary assets and liabilities denominated in currencies other than the US Dollar. Therefore, any change in the relevant exchange rate would require us to recognize a transaction gain or loss on revaluation. For the three-month period ended September 30, 2023, we experienced a foreign currency loss of $18,603 as compared with a foreign currency loss of $320,592 for the three-month period ended September 30, 2022.

Table of Contents

Nine Months Ended September 30, 2023 Compared with the Nine Months Ended September 30, 2022.

The following table sets forth key selected financial data for the nine months ended September 30, 2023 and 2022.

Consolidated

	Nine months ended
	September 30,
	2023			2022
REVENUE	$	7,497,739		$	8,089,132

COST OF REVENUE		(6,434,796	)		(7,169,329	)

GROSS PROFIT		1,062,943			919,803

OTHER INCOME		511,792			153,340

OPERATING EXPENSES
General and administrative		(4,426,077	)		(1,241,631	)

LOSS FROM OPERATIONS		(2,851,342	)		(168,488	)

FINANCE COSTS		(9,746	)		(7,717	)

LOSS BEFORE TAX		(2,861,088	)		(176,205	)

Tax expense		(76,418	)		(22,792	)

NET LOSS	$	(2,937,506	)	$	(198,997	)

Other comprehensive income:
Foreign currency translation loss		(391,533	)		(707,128	)
COMPREHENSIVE LOSS	$	(3,329,039	)	$	(906,125	)

Table of Contents

Segmented Information

segmental reporting for BGLC	MRNA Scientific Malaysia			Chemrex			MRNA Scientific Malaysia			Chemrex
	Nine months ended September 30, 2023						Nine months ended September 30, 2022
REVENUE	$	28,468		$	7,469,271		$	39,409		$	8,049,723

COST OF REVENUE		(14,849	)		(6,419,947	)		(19,173	)		(7,150,156	)

GROSS PROFIT		13,619			1,049,324			20,236			899,567

OTHER INCOME		3,922			507,870			6,617			146,720

OPERATING EXPENSES
General and administrative		(170,590	)		(2,348,127	)		(157,686	)		(906,698	)

(LOSS)/PROFIT FROM OPERATIONS		(153,049	)		(790,933	)		(130,833	)		139,589

FINANCE COSTS		(2,952	)		(6,794	)		(2,196	)		(5,521	)

(LOSS)/PROFIT BEFORE TAX		(156,001	)		(797,727	)		(133,029	)		134,068

Tax expense		-			(76,418	)		-			(22,792	)

NET (LOSS)/PROFIT	$	(156,001	)	$	(874,145	)	$	(133,029	)	$	111,276

Revenue. For the nine months period ended September 30, 2023, we had total revenue of $7,497,739 as compared to total revenue of $8,089,132 for the same period in 2022, which had decreased by $591,393 from the prior period, approximately 7.3% decrease.

Chemrex contributed $7,469,271 (99.6%) of the total revenue for the current nine months period as compared to $8,049,723 (99.5%) of the total revenue for the same period last year. Chemrex’s revenues had decreased by $580,4528 from prior period, approximately 7.21% decrease. The revenue decreased in 2023 was due to competition with reduced selling price for Resin & Fiberglass mat in Malaysia since January 2023 and there was no new project in the market resulted less order from customer.

MRNA Scientific-Malaysia contributed $28,468 (0.4%) of the total revenue for the current nine months in 2023 as compared to revenue of $39,409 (0.5%) of the total revenue from the same period last year. MRNA Scientific-Malaysia’s revenue had decreased by $10,941 from nine months in 2022, an approximately 27.8% decrease. The revenue decreased in 2023 was due to RNA screening process having been adversely impacted by the onset of the Covid-19 pandemic followed by a number of prominent variants, including Alpha, Beta, Delta, and Omicron. Although new variants are an expected part of the evolution of viruses, new variant is more aggressive, highly transmissible, vaccine-resistant, able to cause more severe disease in Malaysia. We believe that most people were reluctant to visit hospitals and clinics in view of the post Covid-19 Omicron and its subvariants for fear of transmission from other patients or medical staff. Since our RNA screening is administered at diagnostic center, our business had been adversely affected as a result.

Cost of Revenue. For the nine months period ended September 30, 2023, we incurred $6,434,796 in cost of revenues, as compared to $7,169,329 for the same period in 2022, decreased by $734,533 approximately 10.2% decrease was due to the same reason stated above.

Chemrex had incurred $6,419,947 (99.8%) of the total cost of revenue during the current period in 2023 as compared to the same period in 2022 last year wherein Chemrex had incurred $7,150,156 (99.7%) of the total in cost of revenue, cost of revenue decreased by $730,209 approximately 10.21% was due to no new project and competition as stated above.

MRNA Scientific-Malaysia had incurred $14,849 (0.2%) of the total cost of revenues during the current period in 2023 as compared to $19,173 (0.3%) for the same period in 2022, cost of revenue decreased by $4,324, approximately 22.6% in cost of revenues for the current period was due to post Covid-19 pandemic as stated above.

Gross Profit. For the nine months period ended September 30, 2023, we had total gross profit of $1,062,943 as compared to gross profit of $919,803 for the same period in 2023, increased by approximately 15.6% from the prior period.

Chemrex contributed $1,049,324 (98.7%) of the total gross profit for the current nine months period as compared to $899,567 (97.8%) of the total gross profit for the same period last year. The gross profit increased by $149,757 approximately 16.65% for current period in 2023 was due to higher gross margin from the old stock that bought at lower prices

Table of Contents

MRNA Scientific-Malaysia had a gross profit of $13,619 (1.3%) of the total gross profit of $1,062,943 for the current nine months period 2023 as compared to $20,236 (2.2%) of the total gross profit of $919,803 from the same period last year 2022. The gross profit decreased by 32.7% was due to its decreased revenues for the current period as according to reason stated above.

Other Income. For the nine months period ended September 30, 2023, we had $511,792 as compared to $153,340 for the same period in 2022, increased by $358,452 approximately 233.8%.

Chemrex contributed $507,870 (99.2%) of other income for the current nine months period as compared to $146,720 (95.7%) of the other income for the same period last year. Chemrex’s other income increased by $361,150 approximately 246.15% was generated from dividend received, bank interest and gain from fair value on investment.

MRNA Scientific-Malaysia had $3,922 (0.8%) for nine months period ended September 30, 2023 as compared to $6,617 (4.3%) for the same period in 2022, decreased by approximately 40.7% was due to lower bank interest earning from lower fund deposited.

Operating Expenses. For the nine months period ended September 30, 2023, we had a total operating expense of $4,426,077 as compared to total operating expenses of $1,241,631 for the same period in 2022. The increase of $3,184,446, approximately 256.5% was due to general and administrative expenses which includes depreciation of fixed assets, employee compensation and benefits, marketing/travel expenses, professional expenses and charges from Advisor, Attorney, STC (Transfer Agent), Finra, Nasdaq and SEC on the Company’s uplisting to Nasdaq, an additional cost for underwriting cost expenses and share-based compensation and provision for losses on account receivables.

Chemrex had incurred $2,348,127(53.1%) of the total operating expenses for the current nine months period in 2023 as compared to $906,698 (73%) of the total operating expenses for the same period 2022 last year, increased by $1,441,429 approximately 158.98% due to the increased commission, directors’ remuneration, medical expenses, loss on unrealized/realized currency exchange, withholding taxes and provision for losses on account receivables of $1,372,573.

MRNA Scientific-Malaysia had incurred $170,590 (3.9%) of the total operating expenses for the current nine months period as compared to $157,686 (12.7%) of the total operating expenses for the same period last year. The increase of $12,904 by approximately 8.2% in operating costs for the nine months period was due to an increase of traveling expenses for marketing, increment of staff remuneration, increase of depreciation of fixed assets for new lab equipment and motor vehicle and additional cost for motor vehicle running expenses.

BGLC, the holding company had incurred $1,907,360 (43.1%) of total operating expenses for the current nine months period as compared to $177,247 (14.3%) of the total operating expenses for the same period last year. The increase of $1,730,113 approximately 976.1% in operating costs of the current period was due to the expenses on filing fees for form S-1, consultant fees for capital & corporation advisory services, fees for three independent board members and audit committee, SEC compliance services, SEC registration fee, shareholders’ notice printing and mailing expenses regarding stock reverse split by Securities Transfer Corporation, an additional review fees for S-1, listing expenses of $205,224 for Nasdaq uplist, the underwriting cost of $660,000 and share-based compensation of $601,740

Loss from Operations. We had a loss from operations of $2,851,342 for nine months period ended September 30, 2023 as compared to loss of $168,488 for the same period in 2022. The increase of $2,682,854, approximately 1592.3% was due to the reasons discussed above.

Income tax expense. For the nine-months period ended September 30, 2023, we had income tax provided by Chemrex $76,418 and MRNA Scientific-Malaysia had no tax provision as compared to the same period 2022 which had a tax estimated $22,792 from Chemrex and no tax provided from MRNA Scientific-Malaysia.

Foreign currency exchange loss. We are exposed to fluctuations in foreign exchange rates on the revaluation of monetary assets and liabilities denominated in currencies other than the US Dollar. Therefore, any change in the relevant exchange rate would require us to recognize a transaction gain or loss on revaluation. For the nine-months period ended September 30, 2023, we experienced a foreign currency loss of $391,533 as compared with a foreign currency loss of $707,128 for the same period in 2022.

Table of Contents

LIQUIDITY AND CAPITAL RESOURCES

As of September 30, 2023, we had working capital of $6,625,767 compared with working capital of $4,017,749 as of December 31, 2022. The increase in working capital as of September 30, 2023 from December 31, 2022 was due principally to the increase in cash generated from our operations.

Our primary uses of cash had been for operations. The main sources of cash was generated from operational revenues and the private placement of our common stock. The following trends could result in a material decrease in our liquidity over the near to long term:

	·	Addition of administrative and marketing personnel as the business grows,
	·	Development of a Company website,
	·	Increases in advertising and marketing in order to attempt to generate more revenues, and
	·	The cost of being a public company.

The Company believes that cash flow from operations together will be sufficient to sustain its current level of operations for at least the next 12 months of operations.

The following is a summary of the Company’s cash flows (used in) / generated from operating, investing, and financing activities for the three months ended September 30, 2023 and 2022:

	Nine months ended
	September 30,
	2023			2022
Net cash (used in)/ generated from Operating Activities	$	(1,039,686	)	$	75,083
Net cash used in investing activities		(368,824	)		(400,595	)
Net cash generated from financing activities		5,743,206			110,441
Foreign currency translation adjustment		(306,677	)		(446,579	)
Net Change in Cash and Cash Equivalents	$	4,028,019		$	(661,650	)

Operating Activities

During the nine months ended September 30, 2023, the Company incurred a net loss of $2,937,506 which, after adjusting for amortization, depreciation, dividend income, fair value gain on share investment, allowances for expected credit losses, share-base compensation, an increase in inventories, a decrease in trade receivables and a substantial reduction in trade payables, operating lease liabilities, advance payment from customer, resulted in net cash of $1,039,686 being used in operating activities during the nine months ended September 30, 2023. By comparison, during the nine months ended September 30, 2022, the Company had a net loss of $198,997 after adjusting for amortization, depreciation, dividend income, fair value loss on share investments and a decrease in inventories, trade receivables, deferred cost of revenue, a substantial reduction in trade payables, operating lease liabilities, advance payment from customer, deferred revenue, resulted in net cash of $75,083 being cash generated from operating activities during the period.

Investing Activities

During the nine months ended September 30, 2023, the Company had net cash of $368,824 used in investment activities from acquisition of share investment of $296,109 and purchase of plant & equipment of $148,461. By comparison during the nine months ended September 30, 2022, the Company had net cash from acquisition of share investment of $397,974 and purchase of plant and equipment of $37,144, resulting in net cash used in investing activities of $400,595.

Financing Activities

During the nine-month ended September 30, 2023, the Company had net cash of $5,743,206 generated from financing activities for shares subscriptions of initial public offering (IPO) of 1,473,500 shares at a price to the public of $4.00 per share for total proceeds of $5,750,000. By comparison during the nine months ended September 30, 2022, we had net cash of $110,441 generated from financing activities for continued the repayment of a finance lease of $34,038 and shares subscriptions of $150,000.

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide information required by this item.

Table of Contents

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

In connection with the preparation of this quarterly report, an evaluation was carried out by the Company’s management, with the participation of the principal executive officer and the principal financial officer, of the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(c) and 15d-15(e) under the Exchange Act (“Exchange Act”) as of September 30, 2023. Disclosure controls and procedures are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the Commission’s rules and forms, and that such information is accumulated and communicated to management, including the principal executive officer and the principal financial officer, to allow timely decisions regarding required disclosures.

Based on that evaluation, the Company’s management concluded, as of the end of the period covered by this report, that the Company’s disclosure controls and procedures were capable in recording, processing, summarizing, and reporting information required to be disclosed, within the time periods specified in the Commission’s rules and forms, and that such information was accumulated and communicated to management, including the principal executive officer and the principal financial officer, to allow timely decisions regarding required disclosures.

Management’s Report on Internal Control over Financial Reporting

The management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting. The Company’s internal control over financial reporting is a process, under the supervision of the principal executive officer and the principal financial officer, designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the Company’s financial statements for external purposes in accordance with United States generally accepted accounting principles (GAAP). Internal control over financial reporting includes those policies and procedures that:

Pertain to the maintenance of records that is in reasonable detail accurately and fairly reflect the transactions and dispositions of the Company’s assets;

ii)

Provide reasonable assurance that transactions are recorded as necessary to permit preparation of the financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with the authorizations of management and the board of directors; and

iii)

Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.

The Company’s management had assessed the effectiveness of our internal control over financial reporting as of September 30, 2023, based on criteria established in Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission, which assessment identified material weaknesses in internal control over financial reporting had improved. A material weakness could create reasonable possibility that a material misstatement in annual or interim financial statements. The management considers its internal control over financial reporting required further improvement.

Management had concluded an internal control over financial reporting and glad to note that a majority of our Board of Directors was made up of independent directors and the Audit Committee comprised of all independent directors since 2023, the adequacy in the monitoring of required internal controls and procedures were improving.

While these control deficiencies did not result in any audit adjustments to our 2023 or 2022 interim or annual financial statements, it could have resulted in a material misstatement that might have been prevented or detected by a segregation of duties.

To the extent reasonably possible, given our limited resources, upon consummation of a merger with a private operating company, the Company had been relying on three or more individuals. We were expanding our current board of directors to include additional independents willing to perform directorial functions. Since the recited remedial actions and we would hire or engage additional personnel, this material weakness would be overcome in the near term. Until such remedial actions could be realized, we would continue to rely on the advice of outside professionals and consultants.

This quarterly report does not include an attestation report of our registered public accounting firm regarding our internal controls over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to Section 404(c) of the Sarbanes-Oxley Act that permit us to provide only management’s report in this annual report.

Changes in Internal Controls over Financial Reporting

During the period ended September 30, 2023, there had been no change in internal control over financial reporting that had materially affected or was reasonably likely to materially affect our internal control over financial reporting.

Table of Contents

PART II OTHER INFORMATION

Item 1. Legal Proceedings.

There are presently no pending legal proceedings to which the Company or any of its property is subject, or any material proceedings to which any director, officer or affiliate of the Company, any owner of record or beneficially of more than five percent of any class of voting securities is a party or has a material interest adverse to the Company, and no such proceedings are known to the Company to be threatened or contemplated against it.

Item 2. Unregistered Sale of Equity Securities and Use of Proceeds.

In August 2023, an aggregate of 759,299 shares of common stock were issued to professional parties in lieu of cash for services rendered in connection with Company’s listing onto the Nasdaq Capital Market, 125,000 were subsequently cancelled in November, 2023. The shares were issued at $0.72 per share. These issuances were made pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act.

In August 2023, an aggregate of 75,000 shares of common stock were issued to directors for services rendered. The shares were issued at $0.72 per share. These issuances were made pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable to our Company.

Item 5. Other Information.

There were issuances of an aggregate total of 1,044,351 shares from July 20,2023 to August 4, 2023 as part of the round-up exercise to the reverse stock split, as detailed in the Schedule 14C filing related to the reverse stock split with the record date May 8^th, 2023.

Table of Contents

Item 6. Exhibits.

Exhibit		Description

31.1		Certification of the Company’s Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002**

31.2		Certification of the Company’s Principal Accounting Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002**

32.1		Certification of the Company’s Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002+**

32.2		Certification of the Company’s Principal Accounting Officer and Principal Financial pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002+**

101.INS		Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).*

101.SCH		Inline XBRL Taxonomy Extension Schema Document.*

101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document.*

101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document.*

101.LAB		Inline XBRL Taxonomy Extension Labels Linkbase Document.*

101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document.*

104		Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).*

__________

+	In accordance with SEC Release 33-8238, Exhibit 32.1 and 32.2 were furnished and not filed.
**	Previously filed or furnished as an exhibit to BioNexus Gene Lab Corp.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023.
*	Furnished with this Form 10-Q/A.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

BIONEXUS GENE LAB CORPORATION

/s/ Su-Leng Tan Lee
Su-Leng Tan Lee
Chief Executive Officer
(Principal Executive Officer)

March 26, 2024

nullnullnullnull

Cover - shares	9 Months Ended
Cover - shares	Sep. 30, 2023	Nov. 20, 2023
Cover [Abstract]
Entity Registrant Name	BIONEXUS GENE LAB CORP.
Entity Central Index Key	0001737523
Document Type	10-Q/A
Amendment Flag	true
Current Fiscal Year End Date	--12-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Current Reporting Status	Yes
Document Period End Date	Sep. 30, 2023
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Entity Ex Transition Period	false
Entity Common Stock Shares Outstanding		17,667,663
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	333-229399
Entity Incorporation State Country Code	WY
Entity Tax Identification Number	35-2604830
Entity Address Address Line 1	Unit 02, Level 10 Tower B, Avenue 3, The Vertical
Entity Address Address Line 2	Business Suite II Bangsar South
Entity Address Address Line 3	No. 8 Jalan Kerinchi
Entity Address City Or Town	Kuala Lumpur
Entity Address Country	MY
Entity Address Postal Zip Code	59200
City Area Code	1307
Local Phone Number	241-6898
Security 12b Title	Common stock, no par value
Trading Symbol	BGLC
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Amendment Description	NA

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2023	Dec. 31, 2022
CURRENT ASSETS
Cash and bank balances	$ 4,704,785	$ 611,849
Fixed deposits placed with financial institutions	1,442,098	1,507,015
Trade receivables	900,396	2,868,364
Other receivables, deposits and prepayments	110,793	25,240
Tax recoverable	3,838	31,551
Inventories	1,107,917	977,807
Total current assets	8,269,827	6,021,826
NON-CURRENT ASSETS
Operating lease right of use assets	147,916	55,730
Property, plant and equipment, net	1,496,562	1,511,708
Other investments	1,551,217	1,150,898
Total non-current assets	3,195,695	2,718,336
TOTAL ASSETS	11,465,522	8,740,162
CURRENT LIABILITIES
Trade payables	1,569,992	1,861,015
Other payables and accrued liabilities	29,776	103,370
Current portion of operating lease liabilities	33,897	16,569
Advance payment from customer	8,218	23,123
Tax payables	2,177	0
Total current liabilities	1,644,060	2,004,077
NON-CURRENT LIABILITIES
Non-current portion of operating lease liabilities	104,867	40,206
Deferred tax liabilities	28,880	30,866
Total non-current liabilities	133,747	71,072
TOTAL LIABILITIES	1,777,807	2,075,149
STOCKHOLDERS' EQUITY
As at September 30, 2023, common stock, no par value; 300,000,000 shares authorized and 17,792,663 shares outstanding, and preferred stock, no par value; 30,000,000 shares authorized and no shares outstanding. As at December 31, 2022, common stock, no par value; 300,000,000 shares authorized and 14,476,513 shares outstanding, and preferred stock, no par value; 30,000,000 shares authorized and no shares outstanding (on a post-reverse stock split basis)*.	17,281,315	10,929,574
Additional paid in capital	(5,011,891)	(5,011,891)
Accumulated (losses)/surplus	(1,781,114)	1,156,392
Accumulated other comprehensive losses	(800,595)	(409,062)
TOTAL STOCKHOLDERS' EQUITY	9,687,715	6,665,013
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 11,465,522	$ 8,740,162

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2023	Dec. 31, 2022
CONDENSED CONSOLIDATED BALANCE SHEETS
Common stock, par value per share	$ 0	$ 0
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares outstanding	17,792,663	14,476,513
Preferred stock, par value per share	$ 0	$ 0
Preferred stock, shares authorized	30,000,000	30,000,000
Preferred stock, shares outstanding	0	0

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)
REVENUE	$ 2,553,686	$ 2,575,086	$ 7,497,739	$ 8,089,132
COST OF REVENUE	2,199,354	2,275,587	6,434,796	7,169,329
GROSS PROFIT	354,332	299,499	1,062,943	919,803
OTHER INCOME	199,284	54,110	511,792	153,340
OPERATING EXPENSES
General and administrative	(3,082,128)	(418,824)	(4,426,077)	(1,241,631)
LOSS FROM OPERATIONS	(2,528,512)	(65,215)	(2,851,342)	(168,488)
FINANCE COSTS	(4,259)	(2,072)	(9,746)	(7,717)
LOSS BEFORE TAX	(2,532,771)	(67,287)	(2,861,088)	(176,205)
Tax expense	(76,418)	(10,114)	(76,418)	(22,792)
NET LOSS	(2,609,189)	(77,401)	(2,937,506)	(198,997)
Other comprehensive income:
Foreign currency translation loss	(18,603)	(320,592)	(391,533)	(707,128)
COMPREHENSIVE LOSS	$ (2,627,792)	$ (397,993)	$ (3,329,039)	$ (906,125)
Earnings per share - Basic and diluted	$ (0.157)	$ (0.028)	$ (0.218)	$ (0.063)
Weighted average shares outstanding and per share amount have been adjusted for the periods shown to reflect the 12-for-1 reverse stock split effected on July 20, 2023, on a retroactive basis as described in Note 10.	16,774,370	14,476,513	15,250,883	14,409,733

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY (Unaudited) - USD ($)	Total	Additional Paid In Capital	Accumulated Surplus/(Loss)	Accumulated Other Comprehensive Income/(Loss)	Common Stock
Balance, shares at Dec. 31, 2021					14,268,180
Balance, amount at Dec. 31, 2021	$ 7,179,779	$ (5,011,891)	$ 1,512,358	$ (100,262)	$ 10,779,574
Net profit for the period	17,066	0	17,066	0	0
Foreign currency translation loss	(68,776)	0	0	(68,776)	$ 0
Balance, shares at Mar. 31, 2022					14,268,180
Balance, amount at Mar. 31, 2022	7,128,069	(5,011,891)	1,529,424	(169,038)	$ 10,779,574
Balance, shares at Dec. 31, 2021					14,268,180
Balance, amount at Dec. 31, 2021	7,179,779	(5,011,891)	1,512,358	(100,262)	$ 10,779,574
Net profit for the period	(198,997)
Balance, shares at Sep. 30, 2022					14,476,513
Balance, amount at Sep. 30, 2022	6,423,654	(5,011,891)	1,313,361	(807,390)	$ 10,929,574
Balance, shares at Mar. 31, 2022					14,268,180
Balance, amount at Mar. 31, 2022	7,128,069	(5,011,891)	1,529,424	(169,038)	$ 10,779,574
Net profit for the period	(138,662)	0	(138,662)	0	0
Foreign currency translation loss	(317,760)	0	0	(317,760)	$ 0
Issuance of shares, shares					208,333
Issuance of shares, amount	150,000	0	0	0	$ 150,000
Balance, shares at Jun. 30, 2022					14,476,513
Balance, amount at Jun. 30, 2022	6,821,647	(5,011,891)	1,390,762	(486,798)	$ 10,929,574
Net profit for the period	(77,401)	0	(77,401)	0	0
Foreign currency translation loss	(320,592)	0	0	(320,592)	$ 0
Balance, shares at Sep. 30, 2022					14,476,513
Balance, amount at Sep. 30, 2022	6,423,654	(5,011,891)	1,313,361	(807,390)	$ 10,929,574
Balance, shares at Dec. 31, 2022					14,476,513
Balance, amount at Dec. 31, 2022	6,665,013	(5,011,891)	1,156,392	(409,062)	$ 10,929,574
Net profit for the period	(69,066)	0	(69,066)	0	0
Foreign currency translation loss	(39,039)	0	0	(39,039)	$ 0
Balance, shares at Mar. 31, 2023					14,476,513
Balance, amount at Mar. 31, 2023	6,556,908	(5,011,891)	1,087,326	(448,101)	$ 10,929,574
Balance, shares at Dec. 31, 2022					14,476,513
Balance, amount at Dec. 31, 2022	6,665,013	(5,011,891)	1,156,392	(409,062)	$ 10,929,574
Net profit for the period	(2,937,506)
Balance, shares at Sep. 30, 2023					17,792,663
Balance, amount at Sep. 30, 2023	9,687,715	(5,011,891)	(1,781,114)	(800,595)	$ 17,281,315
Balance, shares at Mar. 31, 2023					14,476,513
Balance, amount at Mar. 31, 2023	6,556,908	(5,011,891)	1,087,326	(448,101)	$ 10,929,574
Net profit for the period	(259,251)		(259,251)
Foreign currency translation loss	(333,891)			(333,891)
Balance, shares at Jun. 30, 2023					14,476,513
Balance, amount at Jun. 30, 2023	5,963,766	(5,011,891)	828,075	(781,992)	$ 10,929,574
Net profit for the period	(2,609,189)		(2,609,189)
Foreign currency translation loss	(18,603)			(18,603)
Issuance of shares, shares					834,299
Issuance of shares, amount	600,695				$ 600,695
Issuance of shares to underwriter, shares					1,044,351
Issuance of shares to underwriter, amount	1,046				$ 1,046
Round up shares, shares					1,437,500
Round up shares, amount	5,750,000				$ 5,750,000
Balance, shares at Sep. 30, 2023					17,792,663
Balance, amount at Sep. 30, 2023	$ 9,687,715	$ (5,011,891)	$ (1,781,114)	$ (800,595)	$ 17,281,315

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities:
Net loss	$ (2,937,506)	$ (198,997)
Adjustments to reconcile net loss to net cash used in from operating activities:
Amortization of right of use asset	15,620	12,754
Allowances for expected credit losses	1,372,573	0
Bad debts	4,175	0
Depreciation of property, plant and equipment	63,147	66,608
Dividend income	(48,892)	(34,523)
Fair value (gain)/loss on other investments	(223,284)	128,683
Loss on disposal of other investments	0	1,798
Interest	6,794	5,521
Property, plant and equipment written off	18	0
Share-base compensation	601,741	0
Stock written off	392	0
Operating loss before working capital changes	(1,145,222)	(18,156)
Changes in operating assets and liabilities:
Inventories	(130,502)	425,972
Trade and other receivables	505,667	638,401
Deferred cost of revenue	0	67,606
Trade and other payables	(364,617)	(769,436)
Advance payment from customer	(14,905)	(21,810)
Deferred revenue	0	(77,276)
Operating lease liabilities	81,989	(17,009)
Tax recoverable	27,904	(153,209)
Net cash (used in)/generated from operating activities	(1,039,686)	75,083
Cash flows from investing activities:
Acquisition of other investment	(296,109)	(397,974)
Dividend income	48,892	34,523
Purchase of plant and equipment	(148,461)	(37,144)
Proceeds from disposal of other investments	26,854	0
Net cash used in investing activities	(368,824)	(400,595)
Cash flows from financing activities:
Interest	(6,794)	(5,521)
Repayment of finance lease	0	(34,038)
Shares subscriptions	5,750,000	150,000
Net cash generated from financing activities	5,743,206	110,441
Foreign currency translation adjustment	(306,677)	(446,579)
NET CHANGE IN CASH AND CASH EQUIVALENTS	4,028,019	661,650
CASH AND CASH EQUIVALENTS, BEGINNING OF FINANCIAL PERIOD	2,118,864	2,123,919
CASH AND CASH EQUIVALENTS, END OF FINANCIAL PERIOD	6,146,883	1,462,269
CASH AND CASH EQUIVALENTS INFORMATION:
Fixed deposits placed with financial institutions	1,442,098	984,088
Cash at bank	4,704,785	478,181
Cash and cash equivalents, end of financial period	6,146,883	1,462,269
Supplementary cash flow information:
Interest paid	9,746	7,717
Income tax refunded	315	0
Income taxes paid	$ 47,808	$ 123,599

ORGANIZATION AND BUSINESS BACKGROUND

9 Months Ended

Sep. 30, 2023

ORGANIZATION AND BUSINESS BACKGROUND

ORGANIZATION AND BUSINESS BACKGROUND

NOTE 1 – ORGANIZATION AND BUSINESS BACKGROUND

The corporate structure as at September 30, 2023 is depicted below:

	BioNexus Gene Lab Corp., a Wyoming company

100% owned		100% owned
MRNA Scientific Sdn. Bhd. (formerly “Bionexus Gene Lab Sdn. Bhd.”), a Malaysian company		Chemrex Corporation Sdn. Bhd., a Malaysian company

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

Sep. 30, 2023

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

·	Basis of presentation

The accompanying condensed consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”).

·	Basis of consolidation

·	Use of estimates

·	Cash and cash equivalents

·	Trade receivables

·	Inventories

Leases

·	Property, plant and equipment

The principal annual rates used are as follows:

Categories	Principal Annual Rates
Air conditioner		20	%
Buildings		2	%
Computer and software		33	%
Equipment		20	%
Furniture and fittings	10%to20%
Lab Equipment		10	%
Motor vehicle	10%to20%
Office equipment		20	%
Renovation	10%to20%
Signboard		10	%

Fully depreciated plant and equipment are retained in the financial statements until they are no longer in use.

·	Impairment of long-lived assets

·	Revenue recognition

The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements:

·	identify the contract with a customer;
·	identify the performance obligations in the contract;
·	determine the transaction price;
·	allocate the transaction price to performance obligations in the contract; and
·	recognize revenue as the performance obligation is satisfied.

The Company records revenue at point in time which is recognized upon goods delivered or services rendered.

·	Shipping and handling fees

·	Comprehensive income

·	Income taxes

·	Net earnings or loss per share

·	Foreign currencies translation

Translation of amounts from MYR into US$1.00 has been made at the following exchange rates for the respective period and year:

	September 30,		December 31,
	2023		2022
Period ended September 30, 2023 /Year-ended December 31, 2022 US$1: MYR exchange rate		4.6920		4.3900

	January 1, 2023 to September 30, 2023		January 1, 2022 to September 30, 2022
9 months average US$1: MYR exchange rate		4.5192		4.3442

·	Related parties

☐	Fair value of financial instruments

☐	Level 1 : Observable inputs such as quoted prices in active markets;

☐	Level 2 : Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

☐	Level 3 : Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions

☐	Recent accounting pronouncements

☐	Recently Adopted Accounting Standards

TRADE RECEIVABLES

9 Months Ended

Sep. 30, 2023

TRADE RECEIVABLES

TRADE RECEIVABLES

NOTE 3 - TRADE RECEIVABLES

	As of
	September 30,			December 31,
	2023			2022

Trade receivables		2,222,414			2,868,364
Allowances for expected credit losses		(1,322,018	)		-
	$	900,396		$	2,868,364

INCOME TAXES

9 Months Ended

Sep. 30, 2023

INCOME TAXES

INCOME TAXES

NOTE 4 - INCOME TAXES

Provision for income taxes consisted of the following:

United States of America

The Company is registered in the State of Wyoming and is subject to the tax laws of the United States of America.

Malaysia

MRNA Scientific Malaysia and Chemrex are both subject to Malaysia Corporate Tax, which is charged at the statutory income tax rate range of 24% on its assessable income.

	As of
	September 30,			December 31,
	2023			2022
Tax Recoverable
Local	$	-		$	-
Foreign, representing Malaysia		(3,838	)		(31,551	)
Tax Recoverable		(3,838	)		(31,551	)

Income tax liabilities:
Local	$	-		$	-
Foreign, representing Malaysia		2,177			-
Income tax payables		2,177			-

Deferred tax liabilities:
Local	$	-		$	-
Foreign, representing Malaysia		28,880			30,866
Deferred tax liabilities		28,880			30,866
Total		27,219			(685	)

OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES

9 Months Ended

Sep. 30, 2023

OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES

OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES

NOTE 5 – OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES

Operating lease right of use assets as follows:	As of
	September 30,			December 31,
	2023			2022
Balance as of beginning of the period/year	$	55,730		$	41,090
Add: Addition of lease liabilities		110,817			32,281
Less: Amortization		(15,045	)		(15,534	)
Foreign translation differences		(3,586	)		(2,107	)
Balance as of end of the period/year	$	147,916		$	55,730

Operating lease liabilities as follows:
	September 30,			December 31,
	2023			2022
Balance as of beginning of the period/year	$	56,775		$	42,909
Add: Addition of lease liabilities		110,817			30,770
Less: gross repayment		(28,485	)		(19,618	)
Add: imputed interest		3,311			4,913
Foreign translation differences		(3,654	)		(2,199	)
Balance as of end of the year		138,764			56,775
Less: lease liability current portion		(33,897	)		(16,569	)
Lease liability non-current portion	$	104,867		$	40,206

The amortization of the right of use asset for the nine months’ period ended September 30, 2023 and nine months’ period ended September 30, 2022 were $15,620 and $12,754 respectively.

Other information:	As of
	September 30, 2023			December 31, 2022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flow from operating lease	$	81,989		$	(126,686	)
Right of use assets obtained in exchange for operating lease liabilities		147,916			55,730
Remaining lease term for operating lease (years)		4.75			4
Weighted average discount rate for operating lease	$	6.53	%	$	6.40	%

Lease expenses for the nine months’ period ended September 30, 2023 and nine months’ period ended September 30, 2022 were $3,438 and $1,358, respectively.

PROPERTY PLANT AND EQUIPMENT

9 Months Ended

Sep. 30, 2023

PROPERTY PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT

NOTE 6 - PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment consisted of the following:

	As of
	September 30,			December 31,
	2023			2022
Air conditioner	$	1,124		$	1,124
Computer and software		2,516			2,516
Equipment		59,801			60,525
Furniture and fittings		100,118			87,122
Lab equipment		430,742			320,102
Land and buildings		1,506,969			1,506,969
Motor vehicle		161,148			137,914
Office equipment		33,477			38,213
Renovation		98,597			107,414
Signboard		806			704
		2,395,298			2,262,603
(Less): Accumulated depreciation		(638,363	)		(590,317	)
Add: Foreign translation differences		(260,373	)		(160,578	)
Property, plant and equipment, net	$	1,496,562		$	1,511,708

Depreciation expense for the nine months’ period ended September 30, 2023 and 2022 were $63,147 and $66,608 respectively.

OTHER INVESTMENTS

9 Months Ended

Sep. 30, 2023

OTHER INVESTMENTS

OTHER INVESTMENTS

NOTE 7 - OTHER INVESTMENTS

	As of
	September 30,			December 31,
	2023			2022
As of beginning of the period/year	$	1,150,898		$	749,027
Addition during the period/year		296,109			511,706
Disposal during the period/year		(26,854	)		-
Written off during the period/year		-			(1,776	)
Fair value gain/(loss)		223,284			(70,628	)
Foreign exchange translation		(92,220	)		(37,431	)
As of end of the period/year	$	1,551,217		$	1,150,898

The other investments consist of the following shares:
	As of
	September 30,		December 31,
	2023		2022
Investment in quoted shares:
Malaysia		982,257		659,970
Singapore		84,407		101,426
Hong Kong		484,553		389,502
	$	1,551,217	$	1,150,898

TRADE PAYABLES

9 Months Ended

Sep. 30, 2023

TRADE PAYABLES

TRADE PAYABLES

NOTE 8 - TRADE PAYABLES

Trade payables are amounts billed to the Company by suppliers for goods and services in the ordinary course of business. All amounts have short-term repayment terms and vary by supplier.

CONCENTRATION OF RISKS

9 Months Ended

Sep. 30, 2023

CONCENTRATION OF RISKS

CONCENTRATION OF RISKS

NOTE 9 - CONCENTRATION OF RISKS

a) Major customers

During the three months and nine months ended September 30, 2023 and 2022, the Company did not have any material recognizable major customers accounted for 10% or more of the Company’s revenue.

b) Major suppliers

For three months ended September 30, 2023 and 2022, the suppliers who accounted for 10% or more of the Company’s cost of sales and their balances at year ended are presented as follows:

	2023		2022		2023			2022			2023		2022
	Purchase				Percentage of purchases						Accounts payable trade
Vendor A	$	407,094	$	268,101		18.51	%		11.78	%	$	467,447	$	256,536
Vendor B	$	353,697	$	233,770		16.08	%		10.27	%	$	279,092	$	227,124
Vendor C	$	320,413	$	282,848		14.57	%		12.43	%	$	316,067	$	272,734
	$	1,081,204	$	784,719		49.16	%		34.48	%	$	1,062,606	$	756,394

For nine months ended September 30, 2023 and 2022, the suppliers who accounted for 10% or more of the Company’s cost of sales and their balances at year ended are presented as follows:

	2023		2022		2023			2022			2023		2022
	Purchase				Percentage of purchases						Accounts payable trade
Vendor A	$	1,167,862	$	1,012,770		18.15	%		14.13	%	$	316,067	$	272,734
Vendor B	$	1,077,986	$	924,246		16.75	%		12.89	%	$	467,447	$	256,536
Vendor C	$	922,895	$	815,818		14.34	%		11.38	%	$	279,092	$	227,124
	$	3,168,743	$	2,752,834		49.24	%		38.40	%	$	1,062,606	$	756,394

STOCKHOLDERS EQUITY

9 Months Ended

Sep. 30, 2023

STOCKHOLDERS EQUITY

STOCKHOLDERS' EQUITY

NOTE 10 - STOCK HOLDERS’ EQUITY

Reverse Stock Split

The Revised Reverse Stock Split was approved and authorized by a majority of the Company’s stockholder on May 8, 2023 and by the Board of Directors of the Company on May 8, 2023.

Public Offering & Nasdaq Listing

In August, 2023, an aggregate of 75,000 shares of common stock were issued to three directors in lieu of cash for services rendered in connection with their employment as directors of the Company.

From July 20, 2023 to August 4, 2023, an aggregate total of 1,044,351 shares of common stock were issued as part of the round-up exercise to the reverse stock split.

SEGMENTED INFORMATION

9 Months Ended

Sep. 30, 2023

SEGMENTED INFORMATION

SEGMENTED INFORMATION

NOTE 11 – SEGMENTED INFORMATION

	BioNexus Gene Lab Corp., a Wyoming company

100% owned		100% owned
MRNA Scientific Sdn. Bhd. (formerly “Bionexus Gene Lab Sdn. Bhd.”), a Malaysian company		Chemrex Corporation Sdn. Bhd., a Malaysian company

At September 30, 2023, the Company (“BGLC”) operates in the biochemical industry segment through its two Malaysian subsidiaries, MRNA Scientific Malaysia and Chemrex.

For the nine months ended September 30, 2023, segmented (unaudited) revenue and net profit/(loss) (Currency expressed in United States Dollars (“US$”) are as follows:

	MRNA Scientific Malaysia			Chemrex			BGLC			Total
	Nine months ended September 30, 2023

REVENUE	$	28,468		$	7,469,271		$	-		$	7,497,739

COST OF REVENUE		(14,849	)		(6,419,947	)		-			(6,434,796	)

GROSS PROFIT		13,619			1,049,324			-			1,062,943

OTHER INCOME		3,922			507,870			-			511,792

OPERATING EXPENSES
General and administrative		(170,590	)		(2,348,127	)		(1,907,360	)		(4,426,077	)

LOSS FROM OPERATIONS		(153,049	)		(790,933	)		(1,907,360	)		(2,851,342	)

FINANCE COSTS		(2,952	)		(6,794	)		-			(9,746	)

LOSS BEFORE TAX		(156,001	)		(797,727	)		(1,907,360	)		(2,861,088	)

Tax expense		-			(76,418	)		-			(76,418	)

NET LOSS	$	(156,001	)	$	(874,145	)	$	(1,907,360	)	$	(2,937,506	)

	MRNA Scientific Malaysia			Chemrex			BGLC			Total
	Nine months ended September 30, 2022
REVENUE	$	39,409		$	8,049,723		$	-		$	8,089,132

COST OF REVENUE		(19,173	)		(7,150,156	)		-			(7,169,329	)

GROSS PROFIT		20,236			899,567			-			919,803

OTHER INCOME		6,617			146,720			3			153,340

OPERATING EXPENSES
General and administrative		(157,686	)		(906,698	)		(177,247	)		(1,241,631	)

(LOSS)/PROFIT FROM OPERATIONS		(130,833	)		139,589			(177,244	)		(168,488	)

FINANCE COSTS		(2,196	)		(5,521	)		-			(7,717	)

(LOSS)/PROFIT BEFORE TAX		(133,029	)		134,068			(177,244	)		(176,205	)

Tax expense		-			(22,792	)		-			(22,792	)

(LOSS)/PROFIT AFTER TAX	$	(133,029	)	$	111,276		$	(177,244	)	$	(198,997	)

Table of Contents

BIONEXUS GENE LAB CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

	As of September 30, 2023 and December 31, 2022
	Total Assets				Total Liabilities
	2023		2022		2023		2022

BGLC & MRNA Scientific	$	5,002,908	$	677,477	$	176,805	$	108,390
Chemrex		6,462,614		8,062,685		1,601,002		1,966,759
TOTAL		11,465,522		8,740,162		1,777,807		2,075,149

SUBSEQUENT EVENTS

9 Months Ended

Sep. 30, 2023

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS

NOTE 12 – SUBSEQUENT EVENTS

The New Directors began serving their term on December 11, 2023, and their terms shall expire at our annual meeting of stockholders to be held in 2024.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

9 Months Ended

Sep. 30, 2023

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation

The accompanying condensed consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”).

Basis of consolidation

Use of estimates

Cash and cash equivalents

Trade receivables

Inventories

Leases

Property, plant and equipment

The principal annual rates used are as follows:

Categories	Principal Annual Rates
Air conditioner		20	%
Buildings		2	%
Computer and software		33	%
Equipment		20	%
Furniture and fittings	10%to20%
Lab Equipment		10	%
Motor vehicle	10%to20%
Office equipment		20	%
Renovation	10%to20%
Signboard		10	%

Fully depreciated plant and equipment are retained in the financial statements until they are no longer in use.

Impairment of long-lived assets

Revenue recognition

The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements:

·	identify the contract with a customer;
·	identify the performance obligations in the contract;
·	determine the transaction price;
·	allocate the transaction price to performance obligations in the contract; and
·	recognize revenue as the performance obligation is satisfied.

The Company records revenue at point in time which is recognized upon goods delivered or services rendered.

Shipping and handling fees

Comprehensive income

Income taxes

Net earnings or loss per share

Foreign currencies translation

Translation of amounts from MYR into US$1.00 has been made at the following exchange rates for the respective period and year:

	September 30,		December 31,
	2023		2022
Period ended September 30, 2023 /Year-ended December 31, 2022 US$1: MYR exchange rate		4.6920		4.3900

	January 1, 2023 to September 30, 2023		January 1, 2022 to September 30, 2022
9 months average US$1: MYR exchange rate		4.5192		4.3442

Related parties

Fair value of financial instruments

☐	Level 1 : Observable inputs such as quoted prices in active markets;

☐	Level 2 : Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

☐	Level 3 : Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions

Recent accounting pronouncements

Recently Adopted Accounting Standards

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

9 Months Ended

Sep. 30, 2023

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Schedule of Principal Annual Rates

Categories	Principal Annual Rates
Air conditioner		20	%
Buildings		2	%
Computer and software		33	%
Equipment		20	%
Furniture and fittings	10%to20%
Lab Equipment		10	%
Motor vehicle	10%to20%
Office equipment		20	%
Renovation	10%to20%
Signboard		10	%

Schedule of Exchange Rates

	September 30,		December 31,
	2023		2022
Period ended September 30, 2023 /Year-ended December 31, 2022 US$1: MYR exchange rate		4.6920		4.3900

	January 1, 2023 to September 30, 2023		January 1, 2022 to September 30, 2022
9 months average US$1: MYR exchange rate		4.5192		4.3442

TRADE RECEIVABLES (Table)

9 Months Ended

Sep. 30, 2023

TRADE RECEIVABLES

Schedule of Principal Trade Receivable

	As of
	September 30,			December 31,
	2023			2022

Trade receivables		2,222,414			2,868,364
Allowances for expected credit losses		(1,322,018	)		-
	$	900,396		$	2,868,364

INCOME TAXES (Tables)

9 Months Ended

Sep. 30, 2023

INCOME TAXES

Schedule of Deferred Tax Assets and Liabilities

	As of
	September 30,			December 31,
	2023			2022
Tax Recoverable
Local	$	-		$	-
Foreign, representing Malaysia		(3,838	)		(31,551	)
Tax Recoverable		(3,838	)		(31,551	)

Income tax liabilities:
Local	$	-		$	-
Foreign, representing Malaysia		2,177			-
Income tax payables		2,177			-

Deferred tax liabilities:
Local	$	-		$	-
Foreign, representing Malaysia		28,880			30,866
Deferred tax liabilities		28,880			30,866
Total		27,219			(685	)

OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES (Tables)

9 Months Ended

Sep. 30, 2023

OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES

Schedule of operating lease right of use assets

Operating lease right of use assets as follows:	As of
	September 30,			December 31,
	2023			2022
Balance as of beginning of the period/year	$	55,730		$	41,090
Add: Addition of lease liabilities		110,817			32,281
Less: Amortization		(15,045	)		(15,534	)
Foreign translation differences		(3,586	)		(2,107	)
Balance as of end of the period/year	$	147,916		$	55,730

Schedule of the operating lease liability

Operating lease liabilities as follows:
	September 30,			December 31,
	2023			2022
Balance as of beginning of the period/year	$	56,775		$	42,909
Add: Addition of lease liabilities		110,817			30,770
Less: gross repayment		(28,485	)		(19,618	)
Add: imputed interest		3,311			4,913
Foreign translation differences		(3,654	)		(2,199	)
Balance as of end of the year		138,764			56,775
Less: lease liability current portion		(33,897	)		(16,569	)
Lease liability non-current portion	$	104,867		$	40,206

Schedule of Amortization of Right of Use

Other information:	As of
	September 30, 2023			December 31, 2022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flow from operating lease	$	81,989		$	(126,686	)
Right of use assets obtained in exchange for operating lease liabilities		147,916			55,730
Remaining lease term for operating lease (years)		4.75			4
Weighted average discount rate for operating lease	$	6.53	%	$	6.40	%

PROPERTY PLANT AND EQUIPMENT (Tables)

9 Months Ended

Sep. 30, 2023

PROPERTY PLANT AND EQUIPMENT

Schedule of Plant and Equipment

	As of
	September 30,			December 31,
	2023			2022
Air conditioner	$	1,124		$	1,124
Computer and software		2,516			2,516
Equipment		59,801			60,525
Furniture and fittings		100,118			87,122
Lab equipment		430,742			320,102
Land and buildings		1,506,969			1,506,969
Motor vehicle		161,148			137,914
Office equipment		33,477			38,213
Renovation		98,597			107,414
Signboard		806			704
		2,395,298			2,262,603
(Less): Accumulated depreciation		(638,363	)		(590,317	)
Add: Foreign translation differences		(260,373	)		(160,578	)
Property, plant and equipment, net	$	1,496,562		$	1,511,708

OTHER INVESTMENTS (Tables)

9 Months Ended

Sep. 30, 2023

OTHER INVESTMENTS

Schedule of Other Investments

	As of
	September 30,			December 31,
	2023			2022
As of beginning of the period/year	$	1,150,898		$	749,027
Addition during the period/year		296,109			511,706
Disposal during the period/year		(26,854	)		-
Written off during the period/year		-			(1,776	)
Fair value gain/(loss)		223,284			(70,628	)
Foreign exchange translation		(92,220	)		(37,431	)
As of end of the period/year	$	1,551,217		$	1,150,898

Schedule of Other Investments consist of Country

The other investments consist of the following shares:
	As of
	September 30,		December 31,
	2023		2022
Investment in quoted shares:
Malaysia		982,257		659,970
Singapore		84,407		101,426
Hong Kong		484,553		389,502
	$	1,551,217	$	1,150,898

CONCENTRATION OF RISKS (Tables)

9 Months Ended

Sep. 30, 2023

CONCENTRATION OF RISKS

Schedule of Major suppliers Cost Of Sales

	2023		2022		2023			2022			2023		2022
	Purchase				Percentage of purchases						Accounts payable trade
Vendor A	$	407,094	$	268,101		18.51	%		11.78	%	$	467,447	$	256,536
Vendor B	$	353,697	$	233,770		16.08	%		10.27	%	$	279,092	$	227,124
Vendor C	$	320,413	$	282,848		14.57	%		12.43	%	$	316,067	$	272,734
	$	1,081,204	$	784,719		49.16	%		34.48	%	$	1,062,606	$	756,394

	2023		2022		2023			2022			2023		2022
	Purchase				Percentage of purchases						Accounts payable trade
Vendor A	$	1,167,862	$	1,012,770		18.15	%		14.13	%	$	316,067	$	272,734
Vendor B	$	1,077,986	$	924,246		16.75	%		12.89	%	$	467,447	$	256,536
Vendor C	$	922,895	$	815,818		14.34	%		11.38	%	$	279,092	$	227,124
	$	3,168,743	$	2,752,834		49.24	%		38.40	%	$	1,062,606	$	756,394

SEGMENTED INFORMATION (Tables)

9 Months Ended

Sep. 30, 2023

SEGMENTED INFORMATION

Schedule of Segmented Revenue and Net Profit/(Loss)

	MRNA Scientific Malaysia			Chemrex			BGLC			Total
	Nine months ended September 30, 2023

REVENUE	$	28,468		$	7,469,271		$	-		$	7,497,739

COST OF REVENUE		(14,849	)		(6,419,947	)		-			(6,434,796	)

GROSS PROFIT		13,619			1,049,324			-			1,062,943

OTHER INCOME		3,922			507,870			-			511,792

OPERATING EXPENSES
General and administrative		(170,590	)		(2,348,127	)		(1,907,360	)		(4,426,077	)

LOSS FROM OPERATIONS		(153,049	)		(790,933	)		(1,907,360	)		(2,851,342	)

FINANCE COSTS		(2,952	)		(6,794	)		-			(9,746	)

LOSS BEFORE TAX		(156,001	)		(797,727	)		(1,907,360	)		(2,861,088	)

Tax expense		-			(76,418	)		-			(76,418	)

NET LOSS	$	(156,001	)	$	(874,145	)	$	(1,907,360	)	$	(2,937,506	)

	MRNA Scientific Malaysia			Chemrex			BGLC			Total
	Nine months ended September 30, 2022
REVENUE	$	39,409		$	8,049,723		$	-		$	8,089,132

COST OF REVENUE		(19,173	)		(7,150,156	)		-			(7,169,329	)

GROSS PROFIT		20,236			899,567			-			919,803

OTHER INCOME		6,617			146,720			3			153,340

OPERATING EXPENSES
General and administrative		(157,686	)		(906,698	)		(177,247	)		(1,241,631	)

(LOSS)/PROFIT FROM OPERATIONS		(130,833	)		139,589			(177,244	)		(168,488	)

FINANCE COSTS		(2,196	)		(5,521	)		-			(7,717	)

(LOSS)/PROFIT BEFORE TAX		(133,029	)		134,068			(177,244	)		(176,205	)

Tax expense		-			(22,792	)		-			(22,792	)

(LOSS)/PROFIT AFTER TAX	$	(133,029	)	$	111,276		$	(177,244	)	$	(198,997	)

	As of September 30, 2023 and December 31, 2022
	Total Assets				Total Liabilities
	2023		2022		2023		2022

BGLC & MRNA Scientific	$	5,002,908	$	677,477	$	176,805	$	108,390
Chemrex		6,462,614		8,062,685		1,601,002		1,966,759
TOTAL		11,465,522		8,740,162		1,777,807		2,075,149

ORGANIZATION AND BUSINESS BACKGROUND (Details Narrative)	9 Months Ended
	Sep. 30, 2023 shares
BGS Lab Sdn. Bhd [Member]
Business acquisition, business operation description	The principal office address is Unit 02 Level 10, Tower B, Vertical Business Suite, No. 8 Jalan Kerinchi, Bangsar South, 59200 Kuala Lumpur, Malaysia, our lab is located at Lab 353, Chemical Science Centre, University Science Malaysia, George Town, Penang, Malaysia. We also have a blood collection center located at 1st floor, Lifecare Medical Centre, Kuala Lumpur, Malaysia.
Business Acquisition, Effective Date of Acquisition	Aug. 23, 2017
Chemrex Corporation Sdn. Bhd. [Member]
Business aquisition, shares converted	68,487,261

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)	Sep. 30, 2023
Equipment [Member]
Principal Annual Rates	20.00%
Buildings [Member]
Principal Annual Rates	2.00%
Furniture and Fittings [Member] \| Minimum [Member]
Principal Annual Rates	10.00%
Furniture and Fittings [Member] \| Maximum [Member]
Principal Annual Rates	20.00%
Computer and Software [Member]
Principal Annual Rates	33.00%
Motor Vehicle [Member] \| Minimum [Member]
Principal Annual Rates	10.00%
Motor Vehicle [Member] \| Maximum [Member]
Principal Annual Rates	20.00%
Lab Equipment [Member]
Principal Annual Rates	10.00%
Office Equipment [Member]
Principal Annual Rates	20.00%
Renovation [Member] \| Minimum [Member]
Principal Annual Rates	10.00%
Renovation [Member] \| Maximum [Member]
Principal Annual Rates	20.00%
Signboard [Member]
Principal Annual Rates	10.00%
Air Conditioner [Member]
Principal Annual Rates	20.00%

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)	9 Months Ended		12 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Period ended September 30, 2023 /Year-ended December 31, 2022 US$1: MYR exchange rate	4.6920		4.3900
9 months average US$1: MYR exchange rate	4.5192	4.3442

TRADE RECEIVABLES (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
TRADE RECEIVABLES
Trade Receivables	$ 2,222,414	$ 2,868,364
Allowances for expected credit losses	(1,322,018)	0
Total	$ 900,396	$ 2,868,364

TRADE RECEIVABLES (Details Narrative)	9 Months Ended
TRADE RECEIVABLES (Details Narrative)	Sep. 30, 2023
TRADE RECEIVABLES
Description of trade receivable	From July 2023 onwards, Chemrex had increased the interest to 8.4%. Chemrex imposed 6% per annum interest on Mawintech Sdn Bhd since May 2021 till to date. The normal trade credit term is generally on 30 days to 90 days term
Interest rate	6.00%

INCOME TAXES (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Tax Recoverable	$ (3,838)	$ (31,551)
Income tax liabilities	2,177	0
Deferred tax liabilities	28,880	30,866
Total	27,219	(685)
Local [Member]
Tax Recoverable	0	0
Income tax liabilities	0	0
Deferred tax liabilities	0	0
Malaysia [Member]
Tax Recoverable	(3,838)	(31,551)
Income tax liabilities	2,177	0
Deferred tax liabilities	$ 28,880	$ 30,866

INCOME TAXES (Details Narrative)	9 Months Ended
INCOME TAXES (Details Narrative)	Sep. 30, 2023
Malaysia [Member]
Statutory income tax rate	24.00%

OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES
Beginning Balance	$ 55,730	$ 41,090
Add: Addition of lease liabilities	110,817	32,281
Less: Amortization	(15,045)	(15,534)
Foreign translation differences	(3,586)	(2,107)
Ending Balance	$ 147,916	$ 55,730

OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES (Details 1) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Foreign translation differences	$ (3,586)	$ (2,107)
Lease liabilities non-current portion	104,867	40,206
Operating lease liability [Member]
Beginning Balance	56,775	42,909
Add: Addition of lease liabilities	110,817	30,770
Less: gross repayment	(28,485)	(19,618)
Add: imputed interest	3,311	4,913
Foreign translation differences	(3,654)	(2,199)
Ending Balance	138,764	56,775
Less: lease liabilities current portion	(33,897)	(16,569)
Lease liabilities non-current portion	$ 104,867	$ 40,206

OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES (Details 2) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flow from operating lease	$ 81,989	$ (126,686)
Right of use assets obtained in exchange for operating lease liabilities	$ 147,916	$ 55,730
Remaining lease term for operating lease (years)	4 years 9 months	4 years
Weighted average discount rate for operating lease	6.53%	6.40%

OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Lease expenses	$ 3,438	$ 1,358
Amortization of right of use asset	$ 15,620	$ 12,754
Malayan Banking [Member]
Discount rate, effective date	6.40%
Discount rate, initial recognized date	6.65%

PROPERTY PLANT AND EQUIPMENT (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Total Plant and equipment	$ 2,395,298	$ 2,262,603
Less: Accumulated amortization	(638,363)	(590,317)
Add: Foreign translation differences	(260,373)	(160,578)
Property, plant and equipment, net	1,496,562	1,511,708
Equipment [Member]
Total Plant and equipment	59,801	60,525
Computer and Software [Member]
Total Plant and equipment	2,516	2,516
Lab Equipment [Member]
Total Plant and equipment	430,742	320,102
Office Equipment [Member]
Total Plant and equipment	33,477	38,213
Signboard [Member]
Total Plant and equipment	806	704
Air Conditioner [Member]
Total Plant and equipment	1,124	1,124
Furniture and fittings [Member]
Total Plant and equipment	100,118	87,122
Land and buildings [Member]
Total Plant and equipment	1,506,969	1,506,969
Motor Vehicle [Member]
Total Plant and equipment	161,148	137,914
Renovation [Member]
Total Plant and equipment	$ 98,597	$ 107,414

PROPERTY PLANT AND EQUIPMENT (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
PROPERTY PLANT AND EQUIPMENT
Depreciation expense	$ 63,147	$ 66,608

OTHER INVESTMENTS (Details) - USD ($)	9 Months Ended	12 Months Ended
OTHER INVESTMENTS (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
OTHER INVESTMENTS
As of beginning of the year	$ 1,150,898	$ 749,027
Addition during the year	296,109	511,706
Disposal during the year	(26,854)	0
Written off during the period	0	(1,776)
Fair value gain/(loss)	223,284	(70,628)
Foreign exchange translation	(92,220)	(37,431)
As of end of the year	$ 1,551,217	$ 1,150,898

OTHER INVESTMENTS (Details 1) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Other investment	$ 1,551,217	$ 1,150,898
Malaysia [Member]
Other investment	982,257	659,970
Singapore [Member]
Other investment	84,407	101,426
Hong Kong [Member]
Other investment	$ 484,553	$ 389,502

CONCENTRATION OF RISKS (Details) - USD ($)	3 Months Ended		9 Months Ended
CONCENTRATION OF RISKS (Details) - USD ($)	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Concentration of risk purchase	$ 1,081,204	$ 784,719	$ 3,168,743	$ 2,752,834
Percentage of purchases	49.16%	34.48%	49.24%	38.40%
Accounts payable trade	$ 1,062,606	$ 756,394	$ 1,062,606	$ 756,394
Vendor A [Member]
Concentration of risk purchase	$ 407,094	$ 268,101	$ 1,167,862	$ 1,012,770
Percentage of purchases	18.51%	11.78%	18.15%	14.13%
Accounts payable trade	$ 467,447	$ 256,536	$ 316,067	$ 272,734
Vendor B [Member]
Concentration of risk purchase	$ 353,697	$ 233,770	$ 1,077,986	$ 924,246
Percentage of purchases	16.08%	10.27%	16.75%	12.89%
Accounts payable trade	$ 279,092	$ 227,124	$ 467,447	$ 256,536
Vendor C [Member]
Concentration of risk purchase	$ 320,413	$ 282,848	$ 922,895	$ 815,818
Percentage of purchases	14.57%	12.43%	14.34%	11.38%
Accounts payable trade	$ 316,067	$ 272,734	$ 279,092	$ 227,124

STOCK HOLDERS EQUITY (Details Narrative) - USD ($)	1 Months Ended
STOCK HOLDERS EQUITY (Details Narrative) - USD ($)	Jul. 24, 2023	Jul. 20, 2023	Aug. 31, 2023	Jun. 05, 2023
Cede & Company
Common stock, shares issued			1,044,351
Three Directors Member
Common stock, shares issued			75,000
Professional Parties Member
Common stock, shares issued			759,299
Reverse Stock Split Member
Common stock, shares issued				1,044,351
Underwriting Agreement Member
Common stock, shares issued	1,437,500	1,250,000
Public offering price	$ 4.00	$ 4.00
Description of Over allotment option	purchase up to an additional 187,500 shares of common stock at the public offering price of $4.00 per share. The Underwriter fully exercised the Over-Allotment Option on July 24, 2023
Gross proceeds	$ 5,750,000
Underwrinting discount	8.00%
Net proceeds before expenses against issuance of common stock	$ 5,290,000
Additional Underwriting Agreement Member
Common stock, shares issued	115,000
Public offering price	$ 4.40

SEGMENTED INFORMATION (Details) - USD ($)	3 Months Ended						9 Months Ended
SEGMENTED INFORMATION (Details) - USD ($)	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022
REVENUE	$ 2,553,686			$ 2,575,086			$ 7,497,739	$ 8,089,132
COST OF REVENUE	(2,199,354)			(2,275,587)			(6,434,796)	(7,169,329)
GROSS PROFIT	354,332			299,499			1,062,943	919,803
OTHER INCOME	199,284			54,110			511,792	153,340
General and administrative							(4,426,077)	(1,241,631)
LOSS FROM OPERATIONS	(2,528,512)			(65,215)			(2,851,342)	(168,488)
FINANCE COSTS							(9,746)	(7,717)
LOSS BEFORE TAX	(2,532,771)			(67,287)			(2,861,088)	(176,205)
Tax expense							(76,418)	(22,792)
Net loss	$ (2,609,189)	$ (259,251)	$ (69,066)	$ (77,401)	$ (138,662)	$ 17,066	(2,937,506)	(198,997)
Chemrex [Member]
REVENUE							7,469,271	8,049,723
COST OF REVENUE							(6,419,947)	(7,150,156)
GROSS PROFIT							1,049,324	899,567
OTHER INCOME							507,870	146,720
General and administrative							(2,348,127)	(906,698)
LOSS FROM OPERATIONS							(790,933)	139,589
FINANCE COSTS							(6,794)	(5,521)
LOSS BEFORE TAX							(797,727)	134,068
Tax expense							(76,418)	(22,792)
Net loss							(874,145)	111,276
BGLC [Member]
REVENUE							0	0
COST OF REVENUE							0	0
GROSS PROFIT							0	0
OTHER INCOME							0	3
General and administrative							(1,907,360)	(177,247)
LOSS FROM OPERATIONS							(1,907,360)	(177,244)
FINANCE COSTS							0	0
LOSS BEFORE TAX							(1,907,360)	(177,244)
Tax expense							0	0
Net loss							(1,907,360)	(177,244)
MRRNA Scientific Malaysia [Member]
REVENUE							28,468	39,409
COST OF REVENUE							(14,849)	(19,173)
GROSS PROFIT							13,619	20,236
OTHER INCOME							3,922	6,617
General and administrative							(170,590)	(157,686)
LOSS FROM OPERATIONS							(153,049)	(130,833)
FINANCE COSTS							(2,952)	(2,196)
LOSS BEFORE TAX							(156,001)	(133,029)
Tax expense							0	0
Net loss							$ (156,001)	$ (133,029)

SEGMENTED INFORMATION (Details 1) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Total assets	$ 11,465,522	$ 8,740,162
Total Liabilities	1,777,807	2,075,149
Chemrex [Member]
Total assets	6,462,614	8,062,685
Total Liabilities	1,601,002	1,966,759
BGLC & MRNA Scientific [Member]
Total assets	5,002,908	677,477
Total Liabilities	$ 176,805	$ 108,390

BioNexus Gene Lab (PK) (USOTC:BGLC)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more BioNexus Gene Lab (PK) Charts.

BioNexus Gene Lab (PK) (USOTC:BGLC)
Historical Stock Chart
From May 2023 to May 2024

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

BGLC BioNexus Gene Lab Corporation (PK)

BioNexus Gene Lab Corporation (PK) News

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

BGLC BioNexus Gene Lab Corporation (PK)

BioNexus Gene Lab Corporation (PK) News

Your Recent History

Company

Business

Popular

Get The App